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ABSTRACT
Due to the increased prevalence of obesity, non-alcoholic fatty liver disease (NAFLD)
has become a major public health problem in the Western world and Asian countries.
Approximately a third of the general population in the US has NAFLD. NAFLD includes
a spectrum of histological characteristics ranging from simple steatosis to steatohepatitis,
fibrosis and cirrhosis and can be characterized into to two major phenotypes:
nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). Water
disinfection byproducts like trihalomethanes can act as crucial risk factors for NAFLD
progression. Here I have studied the molecular mechanisms of a water disinfection
byproduct, Bromodichloromethane, in induction of hepatic inflammation and
fibrogenesis. I found that Bromodichloromethane (BDCM) can induce hepatic
fibrogenesis and NASH by inducing leptin mediated activation of NADPH oxidase and
subsequent increase in microRNA21 expression, resulting in augmented hepatic TGFβ
signaling. I also explored the hepatoprotective effects of a plant derived TLR4 antagonist
Sparstolonin B (SsnB) and found that it inhibited BDCM induced TLR4-Flottilin colocalization, decreased microRNA21 expression and reduced the expression of a myriad
of inflammatory markers in liver when administered in vivo. Similar effects of SsnB were
also observed in cell culture model of kupffer cells. Anti-fibrotic and anti-proliferative
mechanisms of SsnB were observed in a BDCM induced mice NASH model and in
hepatic stellate cell (HSC) culture. Mechanistically, SsnB decreased activation and profibrogenic proliferation of HSCs. SsnB could inhibit hedgehog signaling pathway,
v

decreased proliferation and induced apoptosis in HSCs. SsnB decreased TGFβ signaling
by upregulating BAMBI and decreased STAT3 activation in HSCs. SsnB also changed
the morphology of fibrogenic stellate cells by downregulating focal adhesion adaptor
protein and stress fibers. Thus, my research unravels novel molecular mechanisms of
hepatic fibrogenesis in NASH and proposes the use of Sparstolonin B to ameliorate
hepatic inflammation and fibrosis in NASH.
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CHAPTER 1
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver
disease in the world with the increased prevalence of obesity and metabolic syndrome(1).
The prevalence of NAFLD is around 30% adult population, 80-90% of obese adults, 3050% diabetic patients and around 90% in patients having hyperlipidemia. In children, the
prevalence of NAFLD is 3-10% rising up to 40-90% in obese children(2). Ranging from
simple fat deposition or steatosis in the liver to nonalcoholic steatohepatitis (NASH),
NAFLD involves a continuum of histological characteristics. Not all individuals having
steatosis develop severe diseases, however, NASH can lead to cirrhosis and end-stage
liver diseases(3). In the United States, NASH is the second most common liver diseases
among the adults who are awaiting liver transplant. The mortality of NASH affected
patients can also increase by cardio-vascular damage. According to the multiple hit
hypothesis of NASH, steatosis makes the liver vulnerable to secondary hits which are
responsible for inducing hepatic inflammation, fibrosis and end stage liver diseases (3).
Increased consumption of high fat diet, excess lipolysis from adipose tissue, decreased fat
export in VLDL (very low-density lipoprotein) form, augmented de novo lipogenesis,
reduced free fatty acid β-oxidation- all these factors can lead to hepatic steatosis. Insulin
resistance

plays

an

important
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role

to

aggravate

this

process by initiating considerable metabolic dysregulation (4). Circulatory cytokines,
hypoxia and death of adipocytes can trigger inflammation in the steatotic liver.
Interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), and CC-chemokine ligand-2
(CCL2) secreted from inflamed adipocytes can regulate insulin resistance, induce
macrophage infiltration and other pro-inflammatory cascades (5). However, adiponectin
secreted by adipocytes is an anti-inflammatory adipokine that enhances insulin
sensitivity, helps in expansion of healthy adipocytes, prevents ectopic lipid deposition
and regulates hepatic β-oxidation of fatty acids (6). Leptin is another adipokine and it
maintains homeostatic control of adipose tissue mass (7). NAFLD is associated with
leptin resistance (8). NASH patients have been found to have higher serum leptin levels
than controls. Leptin has fibrogenic potential. However, serum adiponectin level
decreases in NASH patients compared to healthy controls. Leptin has been found to
augment inflammation, activate hepatic stellate cells, increase TGFβ signaling and induce
insulin resistance. However, adiponectin decreases hepatic stellate cell proliferation,
decreases inflammation and fibrogenesis (9). De novo Lipogenesis, Insulin resistance,
lipotoxicity, mitochondrial dysfunction, Endoplasmic Reticulum stress-all these factors
can facilitate the transition from simple steatosis to NASH (4). Several environmental
pollutants can act as secondary mediators and induce injury in steatotic liver. Studies in
mice, human adults and also children have shown that air pollution can induce insulin
resistance, increase oxidative stress in obese liver and thus plays a chief role on the
development of NAFLD (10). Inhaled particulate matter can increase systemic
inflammation, increase the levels of triglyceride, LDL, VLDL and increased proinflammatory cytokines. In the liver, the particles can induce kupffer cell activation,
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activate JNK, NF-kB, TLR4 signaling pathways, affect PPAR activity, alter glucose and
fat metabolism etc.(11). Heavy metal containing particulate matters, when hit the liver,
can affect lipid metabolism and trigger oxidative stress in the liver (12). Dioxin
contaminants which are generated during incineration of domestic and industrial wastes,
can escape in the nature from the incinerators. They are known to induce steatohepatitis
by down regulating hepatic carboxylesterase 3 (CES3), activating signal transducer and
activator of transcription 3 (STAT3), transforming growth factor (TGFβ), IL-6, and
SMAD signaling pathways (13). Liver plays an important role in detoxification of drugs,
hormones and environmental pollutants. Industrial chemicals, drinking water byproducts
like trihalomethanes (THMs) are known to be associated with fatty liver disease and
hepatic injury. Trihalomethanes are short lived halogenated compounds which are formed
when disinfectants come in contact with natural organic matter. Bromodichloromethane
(BDCM),

trichloromethane

(TCM),

dibromochloromethane

(DBCM)

and

tribromomethane (TBM) are four THMs found in disinfectant treated water and humans
are exposed to them through ingestion, inhalation and dermal as THMs may enter human
body through drinking water, showering, swimming, mopping etc. (14). Several
experimental and epidemiological studies found the association between trihalomethane
expore with hepatic injury and disbetes mellitus (14). A current cross-sectional study
utilizing the U.S. NHANES 1999–2006 data has reported that ALT levels (a marker of
liver injury) was increased in individuals exposed to higher than the median blood
brominated trihalomethane levels (15). As liver metabolizes the xenobiotic compounds in
circulation and process the absorbed contents from the gastrointestinal tract, it is the
primary target organ for human THM exposure which was supported by some previous
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studies from our lab where low acute exposure of bromodichloromethane (BDCM) in diet
induced obese mice was found to generate free radicals followed by CYP2E1 mediated
metabolism resulting in oxidative stress, protein free radical formation and lipid
peroxidation. BDCM induced oxidative stress also promotes glucose transport, glycolysis
and gluconeogenesis resulting in dysfunctional lipid metabolism and NASH development
(16-18). Increased hepatic leptin followed by BDCM exposure in obese mice augmented
hepatic inflammation, kupffer cell activation and hepatic fibrogenesis resulting in NASH
progression (16, 19). In the first chapter of my thesis, I explored the pro-fibrogenic role
of BDCM where BDCM induced NADPH oxidase induced mir21 expression in liver and
increased TGFβ signaling (20).
Alteration of the gut microbiota and induced permeability of intestinal barrier can
also

trigger

hepatic

inflammation

and

metabolic

disorders.

Endotoxins

like

Lipopolysaccharide (LPS) augments NASH pathogenesis as observed in many studies
(21, 22). Stimuli by pathogen associated molecular patterns (PAMPS) are responded by
innate immune response through toll like receptors (TLRs) and NOD-like receptors
(NLRs). Apart from inflammation though gut leaching, tissue injury and cell death can
also induce sterile inflammation and activate TLR4 in liver giving rise to NASH related
liver injury (3). TLR family of receptors can get activated by damage associated
molecular patterns (DAMPs) released during oxidative stress induced tissue injury (23).
Interestingly, BDCM induced NADPH oxidase activation can produce peroxinitrite
which can induce TLR4 recruitment in the lipid rafts, augment TLR4 signaling, increase
IL-1β production, sinusoidal injury and kupffer cell activation resulting in NASH (24).
TLR4 activation can lead to increased IKK and JNK activation, increased NFkB
4

translocation into nucleus etc., which leads to inflammation, fibrosis, insulin resistance
and other metabolic dysregulation during NASH (25-27).
Our collaborators have characterized and published studies of a TLR4 antagonist,
Sparstolonin B (SsnB) derived from a Chinese herb, Sparganium stoloniferum, an herb
historically used in traditional Chinese herbal medicine as an anti-inflammatory, antitumor agent. As identified by NMR and X-ray crystallography, SsnB is a polyphenol
with structural similarities to isocoumarins and xanthone-all these compounds are known
for anti-inflammatory, anti-oxidant and anti-tumor properties (28). SsnB has been shown
to disrupt TLR4 and TLR2 dependent downstream signaling pathways, including NfkB
and MAPK (28). We are the first group to test the therapeutic effect of this compound in
NASH. In the second chapter of my thesis I report that SsnB attenuates of liver
inflammation in early NASH through inhibiting TLR4 migration into the lipid rafts (19).
As chronic inflammation and TLR4 activation leads to increased stellate cell activation
and excessive extracellular matrix deposition in NASH liver (27), we aim to use SsnB to
reduce NASH related liver fibrosis by abrogating the TLR4 signaling. The third and
fourth chapters of this thesis examine the molecular mechanism of SsnB in attenuation of
stellate cell (HSC) activation, proliferation and fibrosis. It is important to target hepatic
stellate cell to attenuate liver fibrosis and cirrhosis. These cells are also involved in liver
cancer and acute liver injury. We found that SsnB significantly decreased stellate cell
activation and proliferation by downregulating pro-fibrogenic cell signaling pathways.
We have also observed that SsnB inhibits the focal adhesion adaptor protein, causes loss
of stress fibers and induces apoptosis in HSCs. Thus, my research provides a novel (i)
mechanistic

and

(ii)

therapeutic

approach
5

for

NASH-prevention/remediation.

CHAPTER 2
MICRO RNA 21 INHIBITION OF SMAD 7 ENHANCES
FIBROGENESIS VIA LEPTIN MEDIATED NADPH OXIDASE IN
EXPERIMENTAL AND HUMAN NONALCOHOLIC
STEATOHEPATITIS1

Dattaroy D, Pourhoseini S, Das S, Alhasson F, Seth RK, Nagarkatti M, Michelotti GA,
Diehl AM, Chatterjee S. Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via
leptin-mediated NADPH oxidase in experimental and human nonalcoholic
steatohepatitis. Am J Physiol Gastrointest Liver Physiol 308: G298–G312, 2015.
Reprinted here with the permission of the publisher.
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Running title: Oxidative stress-miR21 regulation of liver fibrosis
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Abstract:
Hepatic fibrosis in NASH is the common pathophysiologic process resulting from
chronic liver inflammation and oxidative stress. Though significant research has been
carried out on the role of leptin induced NADPH oxidase in fibrogenesis, the molecular
mechanisms that connect leptin-NADPH oxidase axis in upregulation of TGF-β signaling
has been unclear. We aimed to investigate the role of leptin mediated upregulation of
NADPH oxidase and its subsequent induction of miR21 in fibrogenesis. Human NASH
livers and a high fat (60% kCal) diet fed chronic mouse model where hepatotoxin
bromodichloromethane was used to induce NASH, were used for this study. To prove the
role of Leptin-NADPH oxidase-miR21 axis, mouse deficient in genes for leptin, p47phox
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and miR21 were used. Results showed that wild type mice and human livers with NASH
had increased oxidative stress, increased p47phox expression, augmented NF-kB
activation and increased miR21 levels. These mice and human livers showed increased
TGF-β, SMAD2/3-SMAD4 colocalizations in the nucleus, increased Col1α and α-SMA
expression with a concomitant decrease in protein levels of SMAD7. Mice that were
deficient in leptin or p47phox had decreased activated NF-kB and miR21 levels
suggesting the role of leptin and NADPH oxidase in inducing NF-kB mediated miR21
expression. Further miR21 KO mice had decreased co-localization events of SMAD2/3SMAD4 in the nucleus, increased SMAD7 levels and decreased fibrogenesis. Taken
together the studies show the novel role of leptin-NADPH oxidase induction of miR21 as
a key regulator of TGF-β signaling and fibrogenesis in experimental and human NASH.
2.1 INTRODUCTION
Pathogenesis of NASH is not clearly understood and perceived to comprise of an
inflammatory phase of high circulatory leptin, increased oxidative stress, elevated
inflammatory cytokines resulting in hepatocellular injury and subsequent progression into
fibrosis (29). Most NASH pathophysiology is accompanied by a late stage fibrosis (3032). Hepatic fibrosis in NASH most likely occurs from chronic liver inflammation
associated with rise in pro inflammatory cytokines and oxidative stress (33). Fibrosis is
closely linked to accumulation of extracellular matrix (ECM) proteins, mainly type I
collagen, which also can occur in many chronic liver diseases(33). The accumulation of
ECM proteins distorts the hepatic architecture by forming a fibrous scar and the
subsequent development of nodules of regenerating hepatocytes can lead to condition
known as cirrhosis (34). Since NASH might arise almost always from a preexisting
8

condition of obesity, type 2 diabetes, insulin resistance, the higher circulatory levels of
adipose tissue cytokines leptin and TNF-α has been predicted to play a significant role in
hepatic fibrogenesis (35). We and others have shown in rodent models of NASH that
higher leptin is closely associated with fibrosis in NASH (36-38).
Leptin, a product of the ob gene, is synthesized in the liver and the adipose tissue
(39). We have shown that mice fed with a high fat diet and challenged with low doses of
hepatotoxins cause increase in both hepatic and circulatory levels of leptin (17, 40). An
early study by Honda H et al. showed that leptin deficiency is responsible for resistance
to thioacetamide induced fibrogenesis whereas subsequent studies have highlighted the
role of leptin in stellate cell activation, leptin induced TGF-β production via Kupffer cells
and leptin signaling induced collagen production and extracellular matrix formation (4045).
Although leptin has been found to play a distinct role in the stellate cell activation
and TGF-β production, molecular mechanisms involving reactive oxygen species,
especially the role of NADPH oxidase were revealed recently (33). NADPH oxidase ,
both the phagocytic and non-phagocytic isoforms has been detected in the liver cell types
(46). Hepatic stellate cells has been found to express the NADPH oxidase isoform 2
(NOX2) and deletion of one of its cytosolic subunits have resulted in decreased fibrosis
in rodent models of NASH (33). Further published reports from our laboratory have
identified the role of peroxynitrite, a highly reactive nitroso species formed by superoxide
and nitric oxide in NASH (40). We further showed that NADPH oxidase was crucial for
peroxynitrite formation that was again dependent on leptin (40).
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It is also critical that high circulatory levels of leptin accompanied by leptin
resistance are common in patients with liver fibrosis (47). Quiescent hepatic stellate cells
in humans express very low levels of p47phox, a regulatory subunit of NADPH oxidase
but they are highly activated in culture activated stellate cells isolated from patients with
liver fibrosis (48).
Although significant research has been carried out on the leptin induced NADPH
oxidase in fibrogenesis, the molecular mechanisms that connect leptin-NADPH oxidase
axis in upregulation of TGF-β signaling has been unclear. Reactive oxygen species
production by NADPH oxidase, primarily in the form of superoxide or hydrogen
peroxide has been shown to induce nuclear translocation of NF-kB (49). Our unpublished
reports indicate that NF-kB activation led to epigenetic modulations in the form of
upregulation of micro RNA 21 in NASH. Micro RNA 21 (miR21) is a small noncoding
RNA that has been found to have a distinct role in inflammation and their regulatory
functions in NASH pathophysiology are slowly emerging (50, 51).
miR21 upon induction target several proteins either by binding entirely to the
complementary sequence of mRNA of the target protein resulting in a nonfunctional
mRNA or binding partially to cause a translational defect (52). Regulatory protein
SMAD7 which plays an important role in TGF-β signaling, is a target of miR21 and has
been shown to reverse the regulatory effect of this protein (53, 54). Importantly, TGF-β
signaling is crucial to the fibrogenesis in NASH and has been shown conclusively in
many studies (55, 56).
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In this study, we test the hypothesis that high circulatory leptin induced NADPH
oxidase-NF-kB activation causes miR21 mediated SMAD 7 inhibition resulting in
increased TGF-β signaling. The resultant inhibition of SMAD 7 a regulatory SMAD
leads to uninterrupted TGF-β function causing fibrogenesis in NASH. The results
obtained via the use of a rodent model of NASH, human tissues and transgenic mice
lacking leptin, p47phox and miR21 show that leptin induced NADPH oxidase causes
activation of NF-kB and subsequent upregulation of miR21. Lack of miR21 led to
significantly less fibrogenesis, TGF-β production, and downstream signaling of TGF-β
pathway.
2.2 MATERIALS AND METHODS
Obese mice: Adult male, pathogen-free, 6 weeks old mice with C57BL/6J background
(Jackson Laboratories, Bar Harbor, Maine) were used as model for diet induced obesity.
The animals were fed with high-fat diet (60% kcal) from 6 weeks to 16 weeks to develop
diet induced obesity (DIO). After completion of 16 weeks, all experiments were
conducted. Mice which contained disrupted ob gene (leptin) (B6. V-Lepob/J) (Jackson
Laboratories) (ob/ob), another group of leptin knockout mice (ob/ob) treated with leptin
(leptin supplemented group, ob/ob + Leptin), disrupted p47 phox gene(B6.129S2Ncf1tm1shl N14) (Taconic, Cranbury, NJ) (p47 phox KO) and mice with disrupted
microRNA21 gene (B6;129S6-Mir21atm1Yoli/J) (miR21 KO) were fed with a high-fat
diet and treated identically to DIO mice. The mice were housed one per cage in a
temperature-controlled room at 23-24°C with a 12-h/12-h light/dark cycle with libitum
access to food and water. All animals had been treated in strict accordance with the NIH
guideline for Humane Care and Use of Laboratory Animals and local IACUC standards.
11

All experiments were approved by the institutional review board at NIEHS, Duke
University and the University of South Carolina.
Induction of liver injury in obese mice (Toxin Model): Bromodichloromethane
(BDCM) (2.0m mole/kg, diluted in corn oil) was administered through intraperitoneal
injection in 16 weeks old DIO mice (n=6). Liver tissues were collected and pooled after
24 hour exposure of BDCM (DIO+BDCM (24h)) and after 48 hour exposure of BDCM
(DIO+BDCM (48h)). The other group of DIO mice was administered two doses of
BDCM (1.0 mmole/kg, diluted in corn oil)/ week for one week (DIO+BDCM (1w)) and
for four weeks (DIO+BDCM (4w))(n=4). 16 weeks old high fat diet fed DIO mice,
administered with 100ng GdCl3 per day via intraperitoneal route for 4 weeks were also
administered with BDCM (1.0mmole/kg, diluted in corn oil) through the intraperitoneal
route (GdCl3 treated). 16 weeks old high fat diet fed gene specific knockout mice (ob/ob,
p47 phox KO, miR21 KO) mice were administered with BDCM (1.0mmole/kg, diluted in
corn oil) through the intraperitoneal route (n=3). DIO mice was treated with corn oil
(diluent of BDCM) to use as control. After completion of the treatments, all mice were
sacrificed for liver tissue for the further experiments. The tissues were pooled and used
for the study.
Human tissues: Human liver tissues both from NASH and normal individuals were
obtained from NIH repository at University of Minnesota and University of Pittsburg.
Each experiment was carried out using 3 experimental group and 3 control samples.
Histopathology: Liver sections were collected from each animal and fixed in 10%
neutral buffered formalin. These formalin-fixed, paraffin embedded tissues were cut in
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5μm thick sections. These sections were deparaffinized using standard protocol and
stained with Picro-Sirius red. Picro-Sirius red staining of liver sections was done by using
Nova ultra sirius red stain kit following manufacturer’s protocol (IHC world, Woodstock,
MD) and they were observed using 20x objectives under the light microscope.
Immunohistochemistry: Formalin-fixed, paraffin embedded tissues were cut in 5μm
thick sections. Each section was subjected to deparaffinization using standard protocol.
To describe briefly, these sections were washed with two changes of 100% xylene twice
for 3 min followed by xylene: ethanol (1:1) for 3 min, and rehydrated through a series of
ethanol (twice with 100%, 95%, 70%, and 50%), twice with distilled water. The sections
were finally rinsed twice with PBS. Epitope retrieval of the deparaffinized sections was
carried out using epitope retrieval solution and steamer (IHC-World, Woodstock, MD) by
following the manufacturer’s protocol. The primary antibodies 1) anti-3 nitrotyrosine, 2)
anti-TGFβ, 3) anti-CTGF, 4) anti-EDAFN, 5) anti-α-SMA, 6) anti-Col 1α1 were
purchased from Abcam (Cambridge, MA) and used in recommended dilutions. Species
specific biotinylated conjugated secondary antibody and streptavidin conjugated with
HRP were used from Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA) to
perform antigen-specific immunohistochemistry following manufacturer’s protocols. 3,
3’ Diaminobenzidine (Sigma-Aldrich, St.Louis, MO) was used as a chromogenic
substrate. Tissue sections were counter-stained by Mayer’s hematoxylin (Sigma-Aldrich).
Phosphate buffer saline was used for washing thrice between the steps. Sections were
mounted in Simpo mount (GBI Laboratories, Mukilteo, WA) and observed under a 20x
objective. Morphometric analysis was done using CellSens Software from Olympus
America.
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Immuno-fluorescence dual-labelling microscopy: Formalin-fixed, paraffin embedded
tissues were cut in 5μm thick sections. Each section was subjected to deparaffinization
using standard protocol. Epitope retrieval of the deparaffinized sections was carried out
using epitope retrieval solution and steamer (IHC-World, Woodstock, MD) by following
the manufacturer’s protocol. The primary antibodies anti-SMAD2/3, anti-SMAD4, and
anti-gp-91phox, anti-p47phox (purchased from Cell Signaling Technology, MA and
Santa Cruz biotechnology, Inc. Santa Cruz, CA) and used at recommended dilutions.
Species-specific anti-IgG secondary antibodies conjugated with Alexa Fluor 488, Alexa
Fluor633 (Invitrogen, California, USA) were used together against anti-SMAD4 and antiSMAD2/3 respectively. Alexa Fluor 488 and Alexa Fluor 568 were used together against
anti-p47phox and anti-gp91phox respectively. The sections were mounted in a ProLong
gold antifade reagent with DAPI (Life technologies, EU, OR). Images were taken under
20x/60x oil objectives using Olympus BX51 microscope.
Quantitative Real-Time Polymerase Chain Reaction Analysis (qRT-PCR): Real-time
reverse transcription-polymerase chain reaction was done to measure gene expression
(mRNA) levels in the liver tissue samples. Total RNA was isolated from each liver tissue
by homogenization in TRIzol reagent (Life Technologies, Carlsbad, CA) according to
manufacturer’s instruction and was purified by using RNeasy mini kit columns (Qiagen,
Valencia, CA). iScript cDNA synthesis kit (Bio-rad, Hercules, CA) was used to convert
1µg of purified RNA to cDNA following the manufacturer's standard protocol. qRTPCR
was performed with the gene specific primers by using SsoAdvanced universal SYBR
Green supermix (Bio-Rad, Hercules, CA) and CFX96 thermal cycler (Bio-Rad, Hercules,
CA). Threshold Cycle (Ct) values for selected genes were normalized against 18S
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(internal control) values in same sample. For each gene and each tissue sample, each
reaction was carried out in triplicates. Liver sample from DIO mice was used as control
to compare with all other liver samples in the toxin model of NASH. The relative fold
change was calculated by the 2-∆∆Ct method. The primers used for Real time PCR in
5’to 3’ orientation are Human p47phox (Forward: GTACCCAGCCAGCACTATG,
Reverse:

CCTGGCTTTGCTTTCATCTG)

and

Mouse

p47phox

(Forward:

GGTCGACCATCCGCAACGCA, Reverse: TGTGCCATCCGTGCTCAGCG).
miR21 expression levels in liver tissues: Total miRNA was isolated from liver tissue by
homogenization in Qiazol reagent (Qiagen, Valencia, CA) following the manufacturer’s
instructions. The purification was done by using miRNeasy mini kit columns (Qiagen,
Valencia, CA). 1000ng of purified miRNA was converted to cDNA using miScript
cDNA synthesis kit (Qiagen, Valencia, CA) following the manufacturer's protocol.
qRTPCR was performed with microRNA specific primers (Qiagen, Valencia, CA) using
miScript SYBR Green PCR master mix (Qiagen, Valencia, CA) and CFX96 thermal
cycler (Bio-rad, Hercules, CA). Threshold Cycle (Ct) values for the selected gene was
normalized against RNU6-2 (internal miR expression control) values in the same sample.
Western Blotting: 30 mg of each liver tissue was homogenized in 500 µl of RIPA buffer
(Sigma Aldrich) in the presence of phosphatase and protease inhibitor (Pierce, Rockford,
IL) by using dounce homogenizer. After centrifuging the homogenate, the supernatant
was collected for further experiments. 30 µg of protein from each sample was loaded on
4–12% bis-tris gradient gel (Invitrogen, California, USA) for SDS PAGE. By using
precut nitrocellulose/filter paper sandwiches (Bio-Rad Laboratories Inc., California,
USA) and Trans – Blot Turbo transfer system (Bio-Rad), proteins were transferred to
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nitrocellulose membrane. Blots were blocked with 5% non-fat milk solution. Primary
antibody against SMAD7 and β-actin (purchased from Abcam) were used at
recommended dilutions and incubated overnight at 4ºC. Species specific secondary
antibody conjugated with HRP was used. Pierce ECL Western Blotting substrate
(Thermo Fisher Scientific Inc., Rockford, IL) was used. The blot was developed by using
BioMax MS Films and cassettes (with intensifying screen, Kodak). Densitometry
analysis of the images was done using Lab Image 2006 Professional 1D gel analysis
software from KAPLEAN Bioimaging Solutions (Liepzig, Germany).
NF-kB transcription factor binding assay: Nuclear fraction of each liver samples were
isolated by using NF-kB assay kit and following manufacturer’s standard protocol (Five
photon Biochemicals). DNA binding activity of the transcription factor NF-kB present in
those nuclear extracts was detected using enzyme-linked immunosorbent assay (ELISA)
method (Abcam's NF-kB p65 Transcription Factor Assay Kit) following manufacturer’s
standard protocol.
Statistical Analyses: In vivo experiments were repeated two-three times with an average
of 3 mice per group with other in vivo experiments having 4-6 mice/group (n=3/4/6
wherever applicable; data from each group of mice was pooled). The statistical analysis
of data was done by analysis of variance (ANOVA) followed by Bonferroni post-hoc
correction for performing intergroup comparisons. Quantitative data from Western blots,
depicted by the relative intensity of the bands were analyzed by performing student’s t
test. *p<0.05 and #p<0.01 are considered statistically significant.
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2.3 RESULTS
Leptin induces NADPH oxidase subunit p47phox and membrane association with
gp91phox in NASH of both mice and humans. We have shown previously that leptin
induces p47phox in early steatohepatitis leading to the formation of peroxynitrite and
corresponding inflammation and Kupffer cell activation (57). To prove the role of leptin
in induction of p47phox in fibrogenesis of NASH, experiments were performed in both
mice model of NASH and human tissue samples from NASH patients. Results showed
that DIO+BDCM group that shows typical NASH lesions had a 1.6-fold increase in
p47phox mRNA expression as compared to DIO group alone (P<0.05) (Figure 2.1 A).
Leptin knockout (ob/ob) mice showed a significant decrease in p47phox expression as
compared to DIO+BDCM group (P<0.05), while leptin supplementation in leptin
knockout (ob/ob+Leptin) mice resulted in a significant upregulation of p47phox mRNA
as compared to only leptin knockout (ob/ob) mice (P<0.01). Human NASH (Hu NASH)
tissues showed a significant increase p47phox mRNA expression as compared to controls
(Hu CTRL) (P<0.05) (Figure 2.1 B). p47phox subunit of NADPH oxidase requires its
association with its membrane counterpart gp91phox for activation of this enzyme. We
studied the membrane association of these two subunits by immunofluorescence
microscopy in both mice and human tissue samples. Results were analyzed based on the
number of colocalization/overlay events (shown by yellow) per 300 cells counted (Figure
2.1 C and D). Results showed that DIO+BDCM group had a significant increase in the
colocalization events as compared to DIO group only (P<0.01) (Figure 2.1 C and D).
Leptin knockout (ob/ob) mice had a significant decrease in the number of colocalization
events as compared to DIO+BDCM group (P<0.01). Leptin supplemented Leptin
17

Knockout mice (ob/ob+Leptin) had a significant increase in the colocalization events as
compared to leptin knockout (ob/ob) mice (P<0.05) (Figure 2.1 C and D). Human NASH
samples showed a significant increase in the p47phox/gp91phox colocalization as
compared to human controls (Figure 2.1 C and D) (P<0.05). The above results suggest
that leptin induced p47phox expression in NASH and aided in the membrane association
of p47phox and gp91phox that assumes significance in causing oxidative stress in NASH.
Leptin induced NADPH oxidase activation causes peroxynitrite mediated oxidative
stress in both NASH of mice and humans. We have previously shown that
peroxynitrite mediated oxidative stress plays a crucial role in activating Kupffer cells in
early steatohepatitic lesions in NASH (57). To prove that leptin-induced activation of
NADPH oxidase in causing oxidative stress through peroxynitrite formation, experiments
were performed in vivo to estimate 3-nytrotyrosine (3 N-Tyr) immunoreactivity in these
tissues (Figure 2.2). Results showed that 3-nitrotyrosine immunoreactivity was
significantly increased in DIO+BDCM group as compared to DIO group (P<0.05)
(Figure 2.2 A and B). Leptin knockout (ob/ob) mice had a significant decrease in 3nitrotyrosine immunoreactivity as compared to DIO+BDCM group (P<0.05). Leptin
supplemented leptin knockout (ob/ob+Leptin) mice showed a significant increase in the
3-nitrotyrosine immunoreactivity as compared to leptin knockout (ob/ob) mice (P<0.05).
Human NASH samples (n=3) showed a significant increase in 3-nitrotyrosine
immunoreactivity as compared to human controls as shown by morphometry analysis of
the slides (P<0.05) (Figure 2.2 B). All morphometric analysis of the stained liver sections
was expressed as percentage area of immunoreactivity (Figure 2.2 B). The results
suggested that leptin was significantly associated with increase in 3-nitrotyrosine
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immunoreactivity and peroxynitrite might be a prominent player in causing oxidative
stress.
Leptin induced NADPH oxidase activation mediates NF-kB translocation to the
nuclei and upregulation of miR21. NADPH oxidase mediated oxidative stress has been
shown to induce NF-kB translocation (49). NF-kB translocation and its binding to miR21
promoter are crucial for many inflammatory events in disease progression (58). To prove
that leptin, through its activation of NADPH oxidase in vivo causes NF-kB translocation
and binding to DNA, we performed experiments with liver tissue of both mice and
humans. Results showed that NF-kB activation and DNA binding was significantly
increased in DIO+BDCM group as compared to DIO group only (P<0.05) (Figure 2.3 A).
Leptin knockout (ob/ob) mice showed a significant decrease in the NF-kB activation and
binding as compared to DIO+BDCM group (P<0.05). p47phox knockout mice which
cannot participate in NADPH oxidase mediated oxidative stress also showed a significant
decrease in NF-kB activation and binding to DNA as compared to DIO+BDCM group
(P<0.05) (Figure 2.3 A). Human NASH samples from liver showed a significant increase
in NF-kB activation and binding to DNA as compared to corresponding control tissues
(P<0.01) (Figure 2.3 B). DIO+BDCM group had a significant increase in miR21 levels (4
fold) as compared to DIO group (P<0.01) (Figure 2.3 C). Leptin knockout (ob/ob) or
p47phox knockout mice had a significant decrease in miR21 levels as compared to
DIO+BDCM group (P<0.01) (Figure 2.3 C). However Leptin supplementation to leptin
knockout (ob/ob+Leptin) mice had a significant increase in miR21 levels as compared to
leptin knockout (ob/ob) mice and had comparable levels of miR21 with DIO+BDCM
group (P<0.01) (Figure 2.3 C). Human liver samples that had NASH etiology, had
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significantly higher miR21 levels (4.5 fold) as compared to human control tissues
(P<0.01) (Figure 2.3 D). The above results suggested that leptin mediated NADPH
oxidase activation was significantly associated with increased miR21 levels in NASH.
The results assume significance since miR21 mediated repression of its target proteins
can play a major role in disease pathology.
Leptin mediated NADPH oxidase activation and its corresponding induction of
miR21 represses regulatory SMAD protein in both mice and human NASH. miR21
has been found to repress many functional proteins in disease pathology (59). SMAD7, a
regulatory protein in the TGF-β signaling cascade has been shown to be a target for
miR21 (54). We studied the role of Leptin-NADPH oxidase axis in mediating miR21induced SMAD7 repression. Results showed that protein levels of SMAD7 were
significantly elevated during the initial phases of NASH development (DIO+BDCM,
48h) as compared to DIO group. The protein levels of SMAD7 decreased significantly at
1w and at the termination of the study (4w) that showed full-blown NASH symptoms and
correlated well with fibrotic lesions (P<0.05) (Figure 2.4.A and C). miR21 knockout
mice showed a significant increase in SMAD7 protein expression as compared to
DIO+BDCM group at 4 weeks (P<0.01) (Figure 2.4.B and D). Leptin knockout (ob/ob)
mice or p47phox knockout mice or DIO+BDCM mice that were depleted with
macrophage toxin GdCl3 did not show any significant protein levels of Smad7 (Figure
2.4.B and D). This is not surprising since these mice did not have oxidative stress and
there was no induction of SMAD7 in the initial phases (data not shown). Human NASH
tissues showed a significant decrease in SMAD7 protein levels as analyzed by western
blot as compared to corresponding controls (P<0.01) (Figure 2.4.B and D). The results
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suggested that the increased miR21 in mice and human NASH is strongly associated with
decreased SMAD7 protein. The results assume significance since SMAD7 plays a crucial
role in regulating and inhibiting TGF-β signaling, crucial for fibrogenesis in NASH.
Leptin mediated NADPH oxidase activation and corresponding induction of miR21
regulate TGF-β levels in mice and human NASH. TGF-β has been shown to be key
for NASH fibrogenesis (60). To prove the role of leptin mediated NADPH oxidase
induction of miR21 in regulating TGF-β levels in NASH, experiments were performed
with liver slices of mice and human NASH tissues and assessing the immunoreactivity by
using immunohistochemistry. Results showed that DIO+BDCM group had a significantly
increased level of TGF-β as compared to DIO group (P<0.01) (Figure 2.5A and B).
Leptin knockout (ob/ob), p47phox knockout and miR21 knockout mice had a significant
decrease in TGF-β immunoreactivity as compared to DIO+BDCM group (P<0.01)
(Figure 2.5A and B). Leptin supplementation to leptin knockout (ob/ob+Leptin) mice
showed a significant increase in TGF-β immunoreactivity as compared to leptin knockout
(ob/ob) mice alone (P<0.05) (Figure 2.5A and B). Human NASH liver slices showed a
significant increase in TGF-β immunoreactivity as compared to control tissues as shown
by percentage area covered by the immunoreactive staining (morphometric analysis)
(P<0.05) (Figure 2.5A and B). The results suggested that leptin mediated NADPH
oxidase activation and miR21 induction plays a crucial role in TGF-β levels in the livers
of NASH.
Leptin mediated NADPH oxidase activation and corresponding induction of miR21
in NASH are crucial for regulation of SMAD2/3-SMAD4 assembly in the nucleus, a
key event in TGF-β signaling pathway. TGF-β signaling through SMAD2/3 is crucial
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for collagen deposition and fibrogenesis (61-63). It has been shown previously that
SMAD2/3 binds with SMAD4 and translocate to the nucleus. The nuclear colocalization
of the SMAD2/3-SMAD4 heterodimer complex is key event in TGF-β functional
pathway. TGF-β induces heteromeric complexes of SMADs 2, 3 and 4, and their
concomitant translocation to the nucleus, which is required for efficient TGF-β signal
transduction (62). To study the role of leptin mediated NADPH oxidase activation and
miR21 induction in TGF-β signal transduction pathway, experiments were performed
using liver tissue slices. Immunoreactivity to SMAD2/3, SMAD4 and their nuclear
colocalizations were assessed by immunofluorescence microscopy. Results showed that
the number of colocalization events in the nucleus were significantly higher in
DIO+BDCM group as compared to DIO group (P<0.01) (Figure. 2.6A and C). The
colocalization events in the leptin knockout (ob/ob), p47phox knockout and miR21
knockout mice were significantly decreased as compared to DIO+BDCM group (P<0.01
and P<0.05). Leptin supplementation to leptin knockout (ob/ob+ Leptin) mice
significantly increased the number of nuclear colocalization events as compared to leptin
knockout (ob/ob) mice alone (P<0.05). Human NASH samples showed significant
increase in SMAD2/3, SMAD7 nuclear colocalizations as compared to Human liver
controls (P<0.05) (Figure. 2.6A and C). The results were analyzed based on the number
of nuclear colocalizations per 300 cells (Figure. 2.6C). 60X oil micrographs of
DIO+BDCM group in the mouse model and Human NASH liver are shown in
Figure.2.6B. The results show that increased TGF-β induced signaling through SMAD2/3
and SMAD 4 is regulated by leptin mediated NADPH oxidase and its subsequent
upregulation of miR21.
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Leptin mediated NADPH oxidase activation and subsequent miR21 induction
regulate the levels of TGF-β signaling proteins Connective Tissue Growth factor
(CTGF) and EDA-Fibronectin in mice model of NASH and human NASH livers. In
fibrotic liver, connective tissue growth factor (CTGF) is constantly expressed in activated
hepatic stellate cells (HSCs) and acts downstream of TGF-β to modulate extracellular
matrix production (64). On the other hand fibronectin (FN) is a major component of the
extracellular matrix and occurs in two main forms: plasma and cellular FN. The latter
includes the alternatively spliced domain A (EDA) (65). EDA-Fibronectin has been
shown to participate in TGF-β mediated fibroblast differentiation and fibrogenesis (66).
To prove the role of leptin mediated NADPH oxidase activation and subsequent
induction of miR21 in TGF-β signaling, immunohistochemical analysis of the mice liver
and human liver tissues were performed. Results showed that there was a significant
increase in the immunoreactivity of CTGF and EDA-Fibronectin (EDAFN) in
DIO+BDCM group as compared to DIO group (P<0.01and P<0.05) (Figure.2 7A ii and B
ii) (Fig.2 7C and D for morphometric analysis). On the other hand leptin knockout
(ob/ob), p47phox knockout and miR21 knockout mice had a significant decrease in the
CTGF and EDA Fibronectin levels as compared to DIO+BDCM group (Figure.2 7A iii, v
and vi) (2.7B iii, v and vi) (Figure.2.7C and D for morphometric analysis) (P<0.05).
Leptin supplementation in leptin knockout (ob/ob+Leptin) mice showed a significant
increase in the levels of immunoreactivity of both these crucial proteins (P<0.05)
(Figure.2 7A iv and 2.7B iv) (Figure.2 7C and D for morphometric analysis). Human
NASH livers had a significant increase in the immunoreactivity of CTGF and EDAfibronectin as compared to control livers (P<0.05) (Figure.2 7A viii and B viii)

23

(Figure.2.7C and 2.7D for morphometric analysis). The above results show that Leptin
mediated NADPH oxidase activation and subsequent miR21 inhibition of SMAD7 is
closely associated with increased TGF-β signaling resulting in higher CTGF and EDAfibronectin levels in NASH.
Leptin mediated NADPH oxidase activation and miR21 induction cause stellate cell
activation and collagen deposition in NASH. Stellate cell activation is a key event for
NASH progression (16). α-SMA is a biomarker for stellate cell activation (67).
Importantly, increased fibrogenesis and TGF-β signaling results in higher collagen 1α1
level in tissues. To show the role of leptin mediated NADPH oxidase in stellate cell
activation and fibrogenesis, immunohistochemical analyses of mice and human liver
tissues were performed. Results showed that immunoreactivity to α-SMA and Col1α
were significantly high in DIO+BDCM group as compared to DIO group (P<0.01)
(Figure 2.8A ii and 2.8B ii) (morphometric analysis Figure. 2.8C and 2.8D). Leptin
knockout (ob/ob), p47phox knockout and miR21 knockout mice had significantly
decreased immunoreactivity of α-SMA and Col1α as compared to DIO+BDCM group
(P<0.01) (Figure. 2.8A iii, v and vi; 2.8B iii, v and vi) (morphometric analysis
Figure.2.8C and 2.8D). Leptin supplementation in leptin knockout (ob/ob+Leptin) mice
showed a significant increase in the levels of both α-SMA and Col1α as compared to
leptin knockout mice (ob/ob) group alone (P<0.05)(Figure.2.8A iv and 2.8B iv)
(morphometric analysis Figure. 2.8C and 2.8D). Human NASH liver exhibited a
significant increase in α-SMA and Col1αas shown by increased immunoreactivity to
these proteins and morphometric analysis of the tissue staining (P<0.05) (Figure. 2.8A
viii and 2.8B viii) (morphometric analysis Figure.2.8C and 2.8D). The results suggested
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that leptin-mediated NADPH oxidase and the subsequent induction of miR21 regulated
the stellate cell activation and corresponding collagen deposition in both mice and human
NASH livers.
Leptin mediated NADPH oxidase activation and miR21 induction cause fibrogenesis
in NASH. A. Analysis of picrosirius staining for collagen showed increased reactivity in
DIO+BDCM group, especially in the periportal regions as compared to DIO group
(Figure.2.9 A ii). Leptin knockout (ob/ob) or p47phox knockout or miR21 knockout mice
showed a minimal fibrotic stain as compared to DIO+BDCM group (Figure.2.9 A iii, v
and vi). Leptin supplementation sharply increased periportal staining of picrosirius red
(Figure.2.9 A iv) whereas human tissues for NASH showed higher picrosirius red
staining compared to controls (Figure. 2.9 A viii). To show a correlation between the
levels of tissue leptin and fibrotic stage, leptin immunoreactivity in mouse liver
homogenates at 24 h, 48h, 1wk and 4wk as assessed by western blot followed by
normalizations against β-actin (Figure 2.9 B and C) and by picro sirius red staining
depicting fibrosis at 24h, 48h, 1w and 4 w in DIO+BDCM group (Figure 2.9 D).. Results
showed that increased leptin concentrations correlated well with periportal and bridging
fibrosis at 4 weeks following the toxin exposure in an underlying condition of steatosis
(NASH model).
2.4 DISCUSSION
In this study we report for the first time the role of leptin-mediated NADPH oxidase in
inducing miR21 in preclinical NASH model as well as in human NASH patients. We also
show the mechanistic role of miR21 in repressing SMAD7, a crucial regulator of TGF-β
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signaling, thus modulating fibrogenesis in NASH (Figure.2.10). Significantly, the miR21modulation of TGF-β signaling, fibrogenesis and NASH progression were mediated by
NADPH oxidase in our present study. The study assumes huge clinical significance since
the role of NADPH oxidase has been shown in fibrogenesis by us and others but the link
between NADPH oxidase based oxidative stress signaling through posttranscriptional
epigenetic changes and TGF-β signaling remained largely elusive in vivo.
An earlier report from our laboratory showed that leptin-mediated NADPH
oxidase activation activated Kupffer cells largely through the formation of peroxynitrite
in an early stage of steatohepatitic injury (57). Through the present study, we advanced
our understanding about the role of leptin-mediated NADPH oxidase based oxidative
stress in a full blown NASH model and in human NASH livers. The present study used a
rodent model of NASH that had a hepatotoxin bromodichloromethane (BDCM) as a
second hit (16). All our investigations were carried out at a time point where NASH
symptoms were confirmed using clinical indicators. NADPH oxidase subunit p47phox
induction and subsequent activation were observed in these liver tissues (Figure 2.1. AD). The induction and subsequent activation of NADPH oxidase was dependent on the
presence of leptin since leptin knockout mice (ob/ob) or leptin supplementation (100 ng,
daily for 4 weeks) in leptin knockout (ob/ob+Leptin) mice had opposite outcomes (Figure
2.1). Based on our previous reports in the same model, we also established the nature of
the oxidizing species since we observed significant increase in 3-nitrotyrosine
immunoreactivity, a measure for generation of highly reactive peroxynitrite (Figure.2 2A
and B).
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Highly reactive oxidizing species has been shown to induce changes in the epigenetic
foci and cause increases in the expression of non-coding RNAs (68). There are several
miRNAs that are known to be induced in an inflammatory condition (58, 59). NASH has
been shown to induce several miRNAs with specific functions targeted towards its
progression (69-71). miR21 is induced in an inflammatory microenvironment and has
been shown to be induced in disease pathophysiology following the binding of nuclear
transcription factor NF-kB to its promoter (58). In the present study we show that NF-kB
binding activity to the DNA was significantly higher in DIO+BDCM group (NASH
mouse model) and human NASH livers (Figure 2.3A and B). The activation NF-kB was
dependent on leptin and NADPH oxidase activation since leptin knockout (ob/ob) mice
and p47phox knockout mice had significantly lower NF-kB activation (Figure 2.3A).
Human livers had significant increase in NF-kB activation, an index of oxidative stress
and inflammatory signaling pathway (Figure 2.3B). Coupled with the NF-kB activation
our studies also showed that the miR21 levels in the NASH livers were significantly
elevated (Figure 2.3C and D). The levels of the miR21 were dependent on the NADPH
oxidase subunit p47phox and leptin. The results correlate well with observations reported
previously about NF-kB mediated miR21 induction in vitro through a binding of NF-kB
to miR21 promoter region(72). However the above phenomenon could not be established
in the in vivo models of NASH due to procedural complications involving transfection in
primary cells from the NASH mice at this point. Thus it can be justified to assume that
NF-kB translocation in the NASH livers might bind to miR21 promoter causing its
induction, apart from the other functions that it is predicted to perform in NASH (Figure
2.3C and D).

27

A recent review by Noetel et al. describe the current knowledge of the role of miR21 in
liver fibrosis (51). Inflammatory microenvironment in the NASH livers are predicted to
promote TGF-β signaling which in turn can stimulate SMAD2/3 phosphorylation and
their association with SMAD4. Further the above events can up-regulate miR21 which by
suppressing SMAD7 can further add to the increased TGF-β-mediated profibrogenic
responses, events that are known in other fibrotic mechanisms in the lung and kidney (54,
70). We are not aware of any reports that establish a direct role of NADPH oxidase
activation-induced miR21 in TGF-β signaling and subsequent liver fibrosis. To prove the
role of miR21-induced SMAD7 repression and SMAD2/3-SMAD4 interactions, we used
miR21 knockout mice in parallel to p47phox and leptin knockout (ob/ob) mice. Results
showed that miR21 knockout that show significantly lower inflammation in similarly
used NASH models (unpublished data), had higher SMAD7 levels when treated
identically with high fat diet and hepatotoxin challenge as compared to DIO+BDCM
(Figure. 2.4B and D). Interestingly SMAD7 proteins were significantly decreased in
human NASH livers as compared to controls (Figure. 2.4B and D). Leptin knockout
(ob/ob) and p47phox knockout mice had a small increase in protein levels as compared to
DIO+BDCM at 4 weeks but the reported increase was not statistically significant (Fig.
4D). This might be due to the genetic makeup of these mice and a very low level of
inflammation that trigger SMAD 7 protein expression. Also, it’s worth reporting were the
levels of TGF-β in leptin, p47phox and miR21 knockout mice (Figure.2.5A and B).
Results showed that these knockout mice had significantly decreased TGF-β levels as
compared to DIO+BDCM group (Figure.2.5). The results also establish that TGF-β levels
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are significantly regulated upstream of miR21 induction and leptin, NADPH oxidase and
miR21 are linked to cause an upregulation of TGF-β.
TGF-β signaling is crucial for fibrogenesis in NASH. SMAD2/3 association with
SMAD7 in the nucleus is a crucial event in this process (63). This important mechanistic
association and its regulation by miR21 have never been shown in liver fibrosis in vivo or
in human NASH livers. We show by immunofluorescence imaging ex vivo, the
colocalization of SMAD2/3-SMAD4 in the nuclei of NASH livers (Figure.2.6). Murine
and Human NASH livers had a significant increase in the number of colocalization
events as compared to corresponding controls whereas leptin, p47phox and miR21
knockout mice had significantly less number of colocalization events as compared to
NASH groups (Figure.2.6C). The results described in this study assume great
significance since we show that NADPH oxidase through miR21 not only repressed
SMAD7 as a profibrogenic mechanism but also contributed partly to enhance SMAD2/3SMAD4 association in the nucleus, a key event in liver fibrogenesis. The leptin-mediated
NADPH oxidase induction of miR21 also played a significant role in the downstream
events of TGF-β signaling pathway by regulating the levels of CTGF and the intracellular
form of fibronectin (EDA-Fibronectin) (Figure.2.7).
Finally, we studied the implications of the leptin mediated NADPH oxidase
activation and subsequent miR21 upregulation in stellate cell activation, collagen levels
and fibrosis, key events in NASH pathogenesis. Predictably, our results showed a direct
involvement of leptin-mediated NADPH oxidase and miR21 role in fibrogenesis since
leptin knockout (ob/ob), p47phox knockout or miR21 knockout mice had significantly
decreased levels of α-SMA, Col1α and picrosirius red staining as compared to mouse and
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human NASH models (Figure 2.8 and 2.9). Importantly NASH pathogenesis for proving
stellate cell activation and fibrosis in both preclinical and clinical settings rely on the
levels of α-SMA, Col1α and picrosirius red staining.
In summary, we show that leptin mediated NADPH oxidase upregulated the
levels of miR21 through NF-kB activation predictively by binding to the miR21 promoter
in vivo, observations that have been reported previously. The resultant upregulation of
miR21 caused fibrogenesis in NASH by SMAD2/3-SMAD4 association in the nucleus
and SMAD7 repression. Our results will help advance the current knowledge about the
mechanisms of NADPH oxidase mediated fibrogenesis in NASH and will stimulate
newer studies that can help develop therapeutic approaches for this clinically silent
disease.
Acknowledgements: The authors gratefully acknowledge the technical services of
Benny Davidson at the IRF, University of South Carolina, School of Medicine; we also
thank Dr. James Carson, Department of Exercise Science, and the Instrumentation
resource facility (IRF) at the University of South Carolina, School of Medicine for
equipment usage and consulting services.

30

Figure 2.1 Leptin induces NADPH oxidase subunit p47phox and membrane association
with gp91phox. A: qRT-PCR analysis of p47phox mRNA expression of diet-induced
obesity (DIO), DIO + bromodichloromethane (BDCM), ob/ob, and ob/ob + leptin mice
samples normalized against DIO. B: qRT-PCR analysis of p47phox mRNA expression of
human (Hu) nonalcoholic steatohepatitis (NASH) samples normalized against Hu control
(CTRL). C: immunofluorescence dual-labeling microscopy depicting gp91phox (red)p47phox (green) colocalization (yellow) in DIO (i), DIO + BDCM (ii), ob/ob (iii), ob/ob
+ leptin (iv), Hu CTRL (v), and Hu NASH (vi) liver samples taken at ×60 (oil)
magnification. D: morphometric analysis of colocalization events of C, shown in
colocalization events/300-cell unit. *P < 0.05 and #P < 0.01 are considered statistically
significant.
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Figure 2.2 Leptin-induced NADPH oxidase activation causes peroxynitrite-mediated
oxidative stress in NASH of both mice and humans. A: 3-nitrotyrosine (3 N-Tyr)
immunoreactivity as shown by immunohistochemistry in liver slices from the DIO (i),
DIO + BDCM (ii), ob/ob (iii), ob/ob + leptin (iv), Hu CTRL (v), and Hu NASH (vi)
groups, respectively. Images were taken at ×20 magnification. B: morphometric analysis
of the immunoreactivity of A. *P < 0.05 is considered statistically significant.
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Figure 2.3 Leptin-induced NADPH oxidase activation mediates NF-κB activation and
upregulation of micro-RNA 21 (miR21). A: normalized % change of NF-κB activation in
DIO, DIO + BDCM, ob/ob, and p47 phox knockout (KO) samples. B: normalized %
change of NF-κB activation in Hu CTRL and Hu NASH samples. C: qRT-PCR analysis
of miR21 expression of DIO, DIO + BDCM, ob/ob, and ob/ob + leptin mice samples
normalized against DIO. D: qRT-PCR analysis of miR21 expression of Hu NASH
samples normalized against Hu CTRL. *P < 0.05 and #P < 0.01 are considered
significant.
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Figure 2.4 Leptin-mediated NADPH oxidase activation and its corresponding induction
of miR21 repress regulatory SMAD7 protein both in mice and human NASH. A: Western
blot analysis of SMAD7 from liver homogenates of DIO, DIO + BDCM 24 h, DIO +
BDCM 48 h, DIO + BDCM 1 wk (w), and DIO + BDCM 4 w groups, respectively. B:
Western blot analysis of SMAD7 from liver homogenates of DIO, DIO + BDCM 4 w,
ob/ob, ob/ob + leptin, p47phox KO, GdCl3-treated sample, miR21 KO, Hu CTRL, and
Hu NASH groups, respectively. C: immunoreactive band analysis of SMAD7 normalized
against β-actin. y-Axis depicts the SMAD7/actin ratio from DIO, DIO + BDCM 24 h,
DIO + BDCM 48 h, DIO + BDCM 1 w, and DIO + BDCM 4 w groups. D:
immunoreactive band analysis of SMAD7 normalized against β-actin. y-Axis depicts the
SMAD7/actin ratio from DIO, DIO + BDCM 4 w, ob/ob, ob/ob + leptin, p47phox KO,
GdCl3-treated sample, miR21 KO, Hu CTRL, and Hu NASH groups. *P < 0.05 and #P <
0.01
are
considered
statistically
significant.
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Figure 2.5 Leptin-induced NADPH oxidase activation and corresponding induction of
miR21 regulate transforming growth factor (TGF)-β levels in mice and human NASH. A:
TGF-β immunoreactivity as shown by immunohistochemistry in liver slices from the
DIO (i), DIO + BDCM (ii), ob/ob (iii), ob/ob + leptin (iv), p47phox KO (v), miR21 KO
(vi), Hu CTRL (vii), and Hu NASH (viii) groups, respectively. Images were taken at ×20
magnification. B: morphometric analysis of the immunoreactivity of A. *P < 0.05 and #P
<
0.01
are
considered
statistically
significant.
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Figure 2.6 Leptin-mediated NADPH oxidase activation and corresponding induction of
miR21 are crucial for regulation of SMAD2/3-SMAD4 assembly in the nucleus. A:
immunofluorescence dual labeling depicting SMAD2/3 (red)-SMAD4 (green)
colocalization (yellow) in the DIO (i), DIO + BDCM (ii), ob/ob (iii), ob/ob + leptin (iv),
p47phox KO (v), miR21 KO (vi), Hu CTRL (vii), and Hu NASH (viii) liver samples,
taken at ×20 magnification. B: immunofluorescence dual labeling of DIO + BDCM
(mouse) (i) and Hu NASH (human) (ii) liver samples depicting SMAD2/3 (red)-SMAD4
(green) colocalization (yellow) taken at ×60 (oil) magnification. C: morphometric
analysis of colocalization events of A, shown in colocalization events/300-cell unit. *P <
0.05
and
#P
<
0.01
are
considered
statistically
significant.
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Figure 2.7 Leptin-mediated NADPH oxidase activation and subsequent induction of
miR21 regulate TGF-β signaling proteins. Connective tissue growth factor (CTGF) and
extra domain A-fibronectin (EDAFN) in mice and human NASH. A: CTGF
immunoreactivity as shown by immunohistochemistry in liver slices from the DIO (i),
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DIO + BDCM (ii), ob/ob (iii), ob/ob + leptin (iv), p47phox KO (v), miR21 KO (vi), Hu
CTRL (vii), and Hu NASH (viii) groups, respectively. Images were taken at ×20
magnification. B: EDAFN immunoreactivity as shown by immunohistochemistry in liver
slices from the DIO (i), DIO + BDCM (ii), ob/ob (iii), ob/ob + leptin (iv), p47phox KO
(v), miR21 KO (vi), Hu CTRL (vii), and Hu NASH (viii) groups, respectively. Images
were taken at ×20 magnification. C: morphometric analysis of the immunoreactivity of A.
D: morphometric analysis of the immunoreactivity of B. *P < 0.05 and #P < 0.01 are
considered statistically significant.
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Figure 2.8 Leptin-mediated NADPH oxidase activation and miR21 induction cause
stellate cell activation and collagen deposition in NASH. A: α-smooth muscle actin
(SMA) immunoreactivity as shown by immunohistochemistry in liver slices from the
DIO (i), DIO + BDCM (ii), ob/ob (iii), ob/ob + leptin (iv), p47phox KO (v), miR21 KO
(vi), Hu CTRL (vii), and Hu NASH (viii) groups, respectively. Images were taken at ×20
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magnification. B: Col1α1 immunoreactivity as shown by immunohistochemistry in liver
slices from the DIO (i), DIO + BDCM (ii), ob/ob (iii), ob/ob + leptin (iv), p47phox KO
(v), miR21 KO (vi), Hu CTRL (vii), and Hu NASH (viii) groups, respectively. Images
were taken at ×20 magnification. C: morphometric analysis of the immunoreactivity of A.
D: morphometric analysis of the immunoreactivity of B. *P < 0.05 and #P < 0.01 are
considered statistically significant.

Figure 2.9 Leptin-mediated NADPH oxidase activation and miR21 induction cause
fibrogenesis in NASH. A: picrosirius red (PSR) staining of DIO (i), DIO + BDCM (ii),
ob/ob (iii), ob/ob + leptin (iv), p47phox KO (v), miR21 KO (vi), Hu CTRL (vii), and Hu
NASH (viii) liver slices. Fibrosis is depicted by red staining. Images were taken at ×20
magnification. B: leptin immunoreactivity in mouse liver homogenates at 24 h, 48 h, 1
wk, and 4 wk as assessed by Western blot followed by normalizations against β-actin in
C. D: PSR staining depicting fibrosis at 24 h, 48 h, 1 wk, and 4 wk in the DIO + BDCM
group.
*P
<
0.05
is
considered
statistically
significant.
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Figure 2.10 Schematic representation of the role of leptin-induced miR21 in modulating
TGF-β pathway in NASH fibrogenesis. SBE, SMAD binding element.
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CHAPTER 3
SPARSTOLONIN B ATTENUATES EARLY LIVER INFLAMMATION
IN EXPERIMENTAL NASH BY MODULATING TLR4-TRAFFICKING
IN LIPID RAFTS VIA NADPH OXIDASE ACTIVATION.2

2
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Nagarkatti M, Nagarkatti P, Diehl AM, Chatterjee S.Sparstolonin B attenuates early liver
inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via
NADPH oxidase activation. American journal of physiology Gastrointestinal and liver
physiology. 2016;310(7):G510-25.
Reprinted here with permission of publisher.
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Abstract:
Although significant research data exist on the pathophysiology of nonalcoholic
steatohepatitis (NASH), finding an efficient treatment regimen for it remains elusive. The
present study used sparstolonin B (SsnB), a novel TLR4 antagonist derived from the
Chinese herb Sparganium stoloniferum, as a possible drug to mitigate early inflammation
in NASH. This study used an early steatohepatitic injury model in high-fat-fed mice with
CYP2E1-mediated oxidative stress as a second hit. SsnB was administered for 1 wk
along with bromodichloromethane (BDCM), an inducer of CYP2E1-mediated oxidative
stress. Results showed that SsnB administration attenuated inflammatory morphology and
decreased elevation of the liver enzyme alanine aminotransferase (ALT). Mice
administered SsnB also showed decreased mRNA expression of proinflammatory
cytokines TNF-α, IFN-γ, IL-1β, and IL-23, while protein levels of both TNF-α and IL-1β
were significantly decreased. SsnB significantly decreased Kupffer cell activation as
evidenced by reduction in CD68 and monocyte chemoattractant protein-1 (MCP1)
mRNA and protein levels with concomitant inhibition of macrophage infiltration in the
injured liver. Mechanistically, SsnB decreased TLR4 trafficking to the lipid rafts, a
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phenomenon described by the colocalization of TLR4 and lipid raft marker flotillin in
tissues and immortalized Kupffer cells. Since we have shown previously that NADPH
oxidase drives TLR4 trafficking in NASH, we studied the role of SsnB in modulating this
pathway. SsnB prevented NADPH oxidase activation in vivo and in vitro as indicated by
decreased peroxynitrite formation. In summary, the present study reports a novel use of
the TLR4 antagonist SsnB in mitigating inflammation in NASH and in parallel shows a
unique molecular mechanism of decreasing nitrative stress.
Keywords: SsnB, inflammation, NADPH oxidase, p47phox, peroxynitrite
3.1 INTRODUCTION
Nonalcoholic steatohepatitis (NASH), a hepatic manifestation of metabolic syndrome,
arises from an underlying condition of obesity (73).
After nearly three decades there remains a void of drugs approved for the
treatment

of NASH.

Although sufficient

progress

in

the understanding of

pathophysiology, diagnosis, and stages of the disease has been made, a treatment regimen
to cure this metabolic disease remains a challenge. Several treatment modalities have
been tried, yet no single approach has been found to be effective in treating NASH (74).
Lipid-lowering drugs like fibrates and statins have some effect, while insulin sensitizers
(metformin, thiazolidinediones), endocannabinoid receptor agents, ursodeoxycholic acid,
and green tea polyphenols have mixed effects (75). Results from both preclinical and
clinical trials distinctly point to a combinatorial approach (caloric restriction, antiinflammatory, and antioxidant) as a therapeutic remedy for NASH (76-78). Therefore
there is a dire need for sustained research and drug discovery efforts that aim at
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identifying new targets for therapy and eventually combine those that target concomitant
and synergistic pathways of NASH pathogenesis.
As for alcoholic steatohepatitis, Toll-like receptors (TLRs) have been shown to be
involved in the pathogenesis of NASH, as reviewed recently (79, 80). A pioneering study
by Farhadi et al. (81) reported endotoxemia resulting from possible gut leakiness as a
cause for NASH. Later, many reports emerged about the involvement of endotoxin from
the gut as a cause for activation of the TLR4 receptors and the downstream inflammatory
pathways(81-94). We have recently shown (24) that peroxynitrite, a nitrative species
formed from the reaction between superoxide and nitric oxide, is responsible for TLR4
recruitment in lipid rafts. Lipid raft trafficking of TLR4 remains a significant step in
TLR4 signaling and inflammation (95, 96). Upon binding to the TLR4 ligand, it is
rapidly assembled in the lipid-containing domains, an event that is facilitated by NADPH
oxidase (95). Our previously published observations (24) point to the role of peroxynitrite
in contributing to the trafficking of TLR4 in rafts primarily following NADPH oxidase
activation in NASH livers. Abrogation of TLR4 trafficking significantly decreased
inflammation in NASH models and had improved histological outcomes (24). Several
research reports in the past have described TLR4 antagonists and their effectiveness in
attenuating TLR4-based inflammation in disease models (97). Unfortunately, none could
be recommended for therapeutic use in humans. However, the search for an effective
TLR4 antagonist continues owing to the importance of the TLR4 pathway in a myriad of
diseases.
Extending this endeavor in search of an effective TLR4 antagonist, our
collaborators have recently published several research studies that report the effective
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TLR4-antagonizing role of sparstolonin B (SsnB), a natural product derivative (28, 98104). SsnB, an isocoumarin, was isolated from a Chinese herb, Sparganium stoloniferum;
its structure was determined by NMR spectroscopy and X-ray crystallography (28). In
light of the above evidence of SsnB being a potent antagonist for TLR4-induced
inflammation and tissue injury, we tested the hypothesis that administration of SsnB in
murine models of NASH and immortalized Kupffer cells will attenuate early
inflammation and tissue injury induced by TLR4 activation. In the present study we used
a rodent model of NASH in which oxidative stress mediated by CYP2E1, lipotoxicity,
and innate immune mediators were used as “second/multiple hits” to cause NASH.
Results showed that SsnB significantly attenuated TLR4 trafficking to the lipid rafts, a
significant event in TLR4 activation. The effects of SsnB on TLR4 trafficking were also
correlated with a significant inhibition of NADPH oxidase activation and peroxynitrite
formation, an event that was reported by us to be upstream of TLR4 activation in NASH
though TLR4-induced NADPH oxidase activation.
3.2 MATERIALS AND METHODS
Cell culture: Rat immortalized kupffer cell line (Applied Biological Materials Inc.,
Canada) was maintained in complete Dulbecco’s Modified Eagle’s Medium (DMEM,
Corning, VA) supplemented with 10% fetal bovine serum (FBS, Atlas Biologicals, CO)
and 1x Penicillin-Streptomycin solution (Gibco, Life Technologies, NY), and grown at
37°C in a humidified incubator with 5% CO2. HBSS buffer, Tissue culture plastic wares
were purchased from Corning (Corning, VA). Sparstolonin B (SsnB) compound was a
kind gift from our collaborator Dr. Daping Fan (Cell Biology and Anatomy, University of
South Carolina School of Medicine).Stock solution of SsnB was prepared in dimethyl
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sulfoxide (DMSO). The final concentration of SsnB on cells was 100µg/ml, 0.1%
DMSO. The cells were plated on 12 well plates (100,000/well) using DMEM medium
supplemented with 10% FBS. Before treating the cells with LPS (50ng/ml), Leptin
(100ng/ml) and SsnB (100µg/ml), cells were serum starved (DMEM with 0.25% FBS)
for overnight. All treatments are given for 24 hours in 0.25% FBS containing DMEM
medium. Cells treated with 0.1% DMSO were used as control. Cells treated with Leptin
(BioVision, CA) and LPS (Sigma, MO) also had 0.1% DMSO. The cell supernatant was
collected for Nitiric oxide quantification. Cells were plated on coverslips by putting the
coverslips on each well of 12 well plates maintaining the aforementioned conditions and
the cells adhered on coverslips were used for immune-fluorescence dual labelling
staining after completion of the treatment. Primary mice (C57BL6) hepatic macrophages
(ScienCell research lab, Carlsband, CA) were cultured in macrophage specific MaM
media supplemented with MAGS, FBS and P/S (ScienCell research lab, Carlsband, CA)
as instructed by the manufacturer on poly-L-lysine (ScienCell research lab, Carlsband,
CA) coated 12 well plates and incubated at 37°C in a humidified incubator with 5% CO2
to initiate the culture. The cell culture medium was replaced with fresh media in the next
morning and the cells were treated with LPS, LPS and SSnB maintaining the same
concentration and incubation time as mentioned above. Cells, treated with 0.1% DMSO
were used as control.
Mouse Models: Pathogen free, male, C57BL/6J background mice (purchased from
Jackson Laboratories, Bar Harbor, ME) were housed one per cage with a 12-h/12-h
light/dark cycle at 23-24°C at libitum access to food and water. These mice were fed with
60% kcal high fat diet (purchased from Research Diets, New Brunswick, NJ) from 6
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weeks until 16 weeks to generate a model of steatosis (S). Another group of these high fat
diet fed mice, were administered Bromodichloromethane BDCM (1mmol/kg, diluted in
corn oil) intraperitoneally, twice a week for 1 week to generate toxin induced early
steatohepatitic injury model of mice (SH). BDCM and corn oil were purchased from
Sigma-Aldrich (St. Louis, MO).A set of high fat diet fed, BDCM treated mice were
administered with SsnB (3mg/kg-bw) intraperitoneally twice for 1 week (SH+SsnB). A
group of steatotic mice was also administered with SsnB (3mg/kg-bw) intraperitoneally
twice for 1 week (S+SsnB). Age-matched lean control mice (LC) were fed with chow
diet having 10% kcal fat. Another group of chow diet fed lean mice was treated with
same dosage of BDCM for 1 week (LC+BDCM). All animals were treated in strict
accordance with the NIH guideline for Humane Care and Use of Laboratory Animals and
local IACUC standards. All experiments were approved by the institutional review board
at NIEHS, Duke University and the University of South Carolina at Columbia. After
completion of the treatment, mice belonging to all groups were sacrificed for liver tissues
and serum samples for further experiments.
Laboratory analysis
Immunohistochemistry: Mice livers were collected and fixed in 10% neutral buffered
formalin (Sigma Aldrich, Missouri, USA). These formalin-fixed tissues were paraffin
embedded and cut in 5μm thick sections. Using standard protocol (53), these liver
sections were deparaffinized. The deparaffinized sections were subjected to epitope
retrieval of was performed using epitope retrieval solution and steamer (IHC-World,
Woodstock, MD) following the manufacturer’s instructions. The endogenous peroxidases
were blocked by 3% H202. Anti-mouse primary antibodies like anti–IL1β, anti–TNFα,
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anti-MCP1, anti-F4/80, anti-3 Nitrotyrosine (Abcam, Cambridge, MA) were used in
recommended dilutions. Following manufacturer’s protocols (Vectastain Elite ABC kit,
Vector Laboratories, Burlingame, CA), biotinylated conjugated secondary antibody
(species specific) and streptavidin conjugated with HRP were used to perform antigenspecific immunohistochemistry. 3, 3’ Diaminobenzidine (Sigma-Aldrich, St.Louis, MO)
was used as chromogenic substrate. Mayer’s hematoxylin (Sigma-Aldrich) was used as
counterstain. Phosphate buffer saline was used for washing three times between the steps.
Finally, the sections were mounted in Simpo mount (GBI Laboratories, Mukilteo, WA)
and observed under a 20x objective using an Olympus BX51 microscope (Olympus,
America). Morphometric analysis was done using CellSens Software from Olympus
America (Center Valley, PA).
Haematoxylin and Eosin staining: Formalin-fixed tissues were paraffin embedded liver
tissue sections were stained with Haematoxylin and Eosin by the IRF, University of
South Carolina, and School of Medicine.
Serum ALT: Serum samples collected from mice were subjected to alanine
aminotransferase (ALT) analysis (Discovery Life Sciences, CA) according to
manufacturer’s instructions.
Nitric oxide quantification assay: After treating the rat kupffer cells with LPS and
LPS+SsnB (mentioned before), the cell supernatants were collected. The supernatant
collected from the wells, where cells were not treated with LPS or LPS+SsnB, served as a
control. Nitrite was measured in these samples by Griess Reagent System (Promega, WI)
following the manufacturer’s instructions.
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ELISA: After treating the primary mice hepatic macrophages with LPS and LPS+SsnB
(mentioned before), the cell supernatants were collected. The supernatant collected from
the wells, where cells were not treated with LPS or LPS+SsnB, served as a control. TNFα
concentration was measured in these samples by using Mouse TNF ELISA kit (BD
Biosciences, San Jose, CA) following the manufacturer’s instruction.
Immunofluorescence dual-labeling
In vivo: Formalin-fixed, paraffin embedded tissues sections were subjected to
deparaffinization using standard instructions. Epitope retrieval of the deparaffinized
sections was done using epitope retrieval solution and steamer (IHC-World, Woodstock,
MD) following the manufacturer’s protocol. The primary antibodies anti-gp-91phox,
anti-p47phox, Flottilin1, TLR4 (purchased from Santa Cruz biotechnology, Inc. Santa
Cruz, CA and Abcam, Cambridge, MA) and used at recommended dilutions. Speciesspecific anti-IgG secondary antibodies conjugated with Alexa Fluor 488(Invitrogen,
California, USA) was used against anti-p47phox, anti-flottilin1 and Alexa Fluor 633
(Invitrogen, California, USA) was used against anti-gp91 phox and TLR4 respectively.
The sections were mounted in a ProLong gold antifade reagent with DAPI (Life
technologies, EU, OR). Images were taken under 20x and 60x oil objectives using
Olympus BX51 microscope.
In vitro: After completion of the treatments under serum starved condition as the
aforementioned cell culture section, cells attached on coverslips were fixed using 10%
Neutral Buffer Saline. After washing the cells with PBS, containing 0.1% triton x
(Sigma, MO) the cells were blocked using 3% BSA, 0.2% Tween (Fisher, NJ), 10% FBS
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in PBS. Cells were incubated with primary antibodies anti-gp91 phox, anti-p47 phox,
anti-TLR4 (mentioned earlier) and anti-flotillin 2 (Abcam, Cambridge, MA), followed by
species specific Alexa Fluor 633 and 488 (mentioned earlier), for immune-fluorescence
dual labelling staining. Alexa Fluor 633 was used against anti-TLR4 and anti-gp91 phox.
Alexa Fluor 488 was used against anti-flottilin2 and anti- p47 phox. The stained cells
attached on the coverslips were mounted on slides using ProLong gold antifade reagent
with DAPI (Life technologies, EU, OR) and viewed under 40x and 60x oil objectives
using Olympus BX51 microscope.
Quantitative Real-Time Polymerase Chain Reaction: Gene expression (mRNA) levels
in the mice liver tissue samples and mouse primary hepatic macrophages were measured
by real-time reverse transcription-polymerase chain reaction (qRTPCR). Total RNA was
isolated from liver tissues and mouse primary hepatic macrophages using TRIzol reagent
(Life Technologies, Carlsbad, CA). Trizol reagent is used to lyse the tissue, RNA
extraction and purification are carried out by using RNeasy mini kit columns (Qiagen,
Valencia, CA) following manufacturer’s protocol. 1µg of purified RNA was converted to
cDNA by using iScript cDNA synthesis kit (Bio-rad, Hercules, CA). Quantitative realtime reverse transcription-polymerase chain reaction was performed with the gene
specific primers using CFX96 thermal cycler (Bio-Rad, Hercules, CA) and SsoAdvanced
universal SYBR Green supermix (Bio-Rad, Hercules, CA). Threshold Cycle (Ct) values
for genes of interest were normalized against 18S (internal control) values in same
sample. Reaction was carried out in triplicates for each gene and each tissue sample. The
relative fold change was calculated by the 2-∆∆Ct method. The mouse specific primers
used

for

Real

time

PCR

in

5’to
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3’

orientation

are

IL1β

(Forward:

CCTCGGCCAAGACAGGTCGC,
TNFα

(Forward:

Reverse

TGCCCATCAGAGGCAAGGAGGA),

CAACGCCCTCCTGGCCAACG,

Reverse:

TCGGGGCAGCCTTGTCCCTT), IFNγ (Forward: TGCGGGGTTGTATCTGGGGGT,
Reverse:

IFNγ

GCGCTGGCCCGGAGTGTAG),

(Forward:

TGCGGGGTTGTATCTGGGGGT, Reverse: GCGCTGGCCCGGAGTGTAG), IL23
(Forward:

AAAGGATCCGCCAAGGTCTG,

GCAGGCTCCCCTTTGAAGAT),

CD68

Reverse:
(Forward:

GCTACATGGCGGTGGAGTACAA, Reverse: ATGATGAGAGGCAGCAAGATGG),
MCP1(Forward:

CACAGTTGCCGGGCTGGAGCAT,

GTAGCAGCAGGTGAGTGGGGC),

P47phox

Reverse:
(Forward:

GGTCGACCATCCGCAACGCA, Reverse: TGTGCCATCCGTGCTCAGCG), TLR4
(Forward:

GGAGTGCCCCGCTTTCACCTC,

Reverse:

ACCTTCCGGCTCTTGTGGAAGC).
miRNA21 expression levels in liver tissues: Liver tissues were homogenized in Qiazol
reagent (Qiagen, Valencia, CA) following the manufacturer’s instructions to isolate the
total miRNA. The purification was done by using miRNeasy mini kit columns (Qiagen,
Valencia, CA). 100ng of purified miRNA was converted to cDNA using miScript cDNA
synthesis kit (Qiagen, Valencia, CA) using the manufacturer's protocol. qRTPCR was
performed with microRNA specific primers (Qiagen, Valencia, CA) using miScript
SYBR Green PCR master mix (Qiagen, Valencia, CA) and CFX96 thermal cycler (Biorad, Hercules, CA). Threshold Cycle (Ct) values for the selected gene was normalized
against RNU6-2 (internal miRNA expression control) values in the same sample.
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Western Blotting: In the presence of phosphatase and protease inhibitors (Pierce,
Rockford, IL), 30 mg of each liver tissue was homogenized in 500 µl of RIPA buffer
(Sigma Aldrich) by using dounce homogenizer. The homogenate was centrifuged and the
supernatant was collected for further experiments. 25 µg of each protein sample was
loaded on 4–12% bis-tris gradient gel (Invitrogen, California, USA) for SDS PAGE. By
using precut nitrocellulose/filter paper sandwiches (Bio-Rad Laboratories Inc.,
California, USA ) and Trans – Blot Turbo transfer system (Bio-Rad), proteins were
transferred to nitrocellulose membrane. Blots were blocked with 5% non-fat milk
solution. Primary antibody against PTEN, β-actin (purchased from Abcam, MA) and
TLR4 (Santa Cruz Biotechnology, CA) were used at recommended dilutions and
incubated overnight at 4ºC. Species specific secondary antibodies conjugated with HRP
(Abcam, MA) were used and the blots were incubated at room temperature for 2 hours.
Pierce ECL Western Blotting substrate (Thermo Fisher Scientific Inc., Rockford, IL) was
used. The blot was developed by using BioMax MS Films and cassettes (with
intensifying screen, Kodak). Densitometry analysis of the images was done using Lab
Image 2006 Professional 1D gel analysis software from KAPLEAN Bioimaging
Solutions (Liepzig, Germany).
Statistical Analyses: The statistical analysis was performed by analysis of variance
(ANOVA) which was followed by Bonferroni post-hoc correction for intergroup
comparisons *p<0.05 and #p<0.01 are considered statistically significant.
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3.3 RESULTS
SsnB administration attenuates early steatohepatitic injury in obese mice. Feeding
high fat diet to C57BL6/J mice for 4 weeks starting from 8 weeks post gestational age
causes insulin and leptin resistance, steatosis but does not cause inflammation, tissue
injury and fibrosis(40). Nonalcoholic steatohepatitis (NASH) can be a result of multiple
hits that may include oxidative stress, increased CYP2E1 activity, cytokine release and/or
altered metabolism(105). We used a toxin-induced steatohepatitis and lipotoxicity model
in mice to show the therapeutic effects of SsnB(38) . Results showed that SsnB
administration markedly decreased necrosis, ballooning, Mallory denk bodies and
inflammatory foci in steatohepatitis group (SH) (Figure 3.1 A). SsnB administration
significantly decreased the levels of serum ALT as compared to SH group but was
significantly higher than the steatosis (S) group (Figure 3.1 B) (P<0.05).
NASH is known to have a significant proinflammatory phase primarily arising
from activation of pattern recognition receptors (PRRs) in the liver primarily from higher
endotoxin levels, HMGB1 or other endogenous ligands(90, 106). To study the effect of
SsnB administration to SH mice, liver proinflammatory cytokine gene and protein levels
were analyzed by qrtpcr and immunohistochemistry. Results showed that as expected,
mRNA expression of TNF-α, IFN-γ and IL1β, which are proinflammatory in nature were
significantly elevated in SH group as compared to S only group (Figure.3.2A)(P<0.05).
IL23 is known as a marker for M1 polarization(107, 108). Results showed that mRNA
expression of IL23 also was significantly upregulated in SH group when compared to S
only group (Figure.3.2A)(P<0.05). SsnB administration significantly decreased the
mRNA expression of proinflammatory markers TNFα, IFNγ, IL1β and macrophage
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polarization marker IL23 when compared to SH group (Figure.3.2A)(p<0.05). Since
TLR4 activation has been shown to be major event in progression of nonalcoholic
steatohepatitis we studied the downstream proinflammatory molecules for this important
pathway. Results showed that there was a significant increase in TNF-α and IL1β
immunoreactivity in liver slices from SH mice when compared to S group only
(Figure.3.2B, C and D)(P<0.05). The localization of the cytokines was unevenly
distributed with TNFα localized in the centrilobular regions while IL1β at both Zone1
and Zone 3 respectively (Figure.3.2B). SsnB administration significantly decreased the
immunoreactivity of both TNFα and IL1β in liver tissue when compared to SH group
mice (Figure3.2B, C and D)(P<0.05).
SsnB administration modulates Kupffer cell activation in early steatohepatitic
injury. NASH is associated with activation of the resident macrophages in the liver(40).
Kupffer cells has been shown to migrate more towards Zone-3 in liver injury, generate
reactive oxygen species, release proinflammatory cytokines and chemokines and play a
significant role in inflammatory mechanisms in NASH(44). We examined the role of
SsnB in modulating Kupffer cell activation in vivo by studying the mRNA and
immunoreactivity of Kupffer cell activation marker CD68 and monocyte chemoattractant
protein-1 (MCP-1) in the injured livers. Results showed that SsnB administration
significantly decreased mRNA expression of both CD68 and MCP-1 (decrease of more
than 12 fold for CD68) (Figure.3.3A) (P<0.05). Immunoreactivity to MCP1 were also
significantly decreased in SH mice that were administered SsnB when compared to SH
mice alone suggesting a possibility of low leukocyte infiltration in the liver lobule
(Figure 3.3B, upper panel, C-morphometric analysis) (P<0.05). To examine the extent of
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leukocyte infiltration in the liver lobule immunoreactivity to pan macrophage marker
F4/80 was studied using immunohistochemistry. Results showed that there were
significant increases in F4/80 immunoreactivity in the injured liver when compared to S
group alone while administration of SsnB significantly attenuated the leukocyte
infiltration as evidenced by decreased immunoreactivity to F4/80 in the liver (Figure. 3.3
B-down panel, 3D-morphometry) (p<0.05).
SsnB administration attenuates miR21 expression and repression of phosphatase
and Tensin homologue (PTEN). We have shown previously that steatohepatitic injury
following obesity causes a marked increase in miR21 expression, a non-coding RNA that
has significant regulatory role in liver inflammation(109, 110). Higher miR21 levels led
to decreased GRHL3 and SMAD7 proteins in both human NASH and rodent models of
obesity(109, 110). Since TLR4 has been shown to play a role in miR21 induction, we
studied the effects of SsnB, a probable TLR4 antagonist in TLR4-induced miR21
pathway. Results showed that SH mice had a significant increase in mir21 expression
while administration of SsnB markedly decreased its expression in the murine obese liver
(over 3 fold decrease) (Figure 3.4A)(P<0.05). SsnB administration also decreased the
levels of PTEN, a direct target of miR21 in the liver as shown by western blot analysis
when compared to SH group (Figure 3.4B and C)(P<0.05). The results suggested that
SsnB might have a role in decreasing miR21 induced repression of PTEN primarily by
blocking TLR4 activation however the interpretation of a SsnB role in blocking TLR is
speculative at this time.
SsnB targets TLR4 trafficking to lipid rafts. Many studies, including ours have shown
a direct role of TLR4 activation in both alcoholic and nonalcoholic steatohepatitis (80,
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95, 111). One of the key aspects of TLR4 activation is its trafficking to lipid rich domains
on the plasma membrane(95). Upon binding to a specific TLR4 ligand which can include,
lipopolysaccharide (LPS), HMGB1 or free fatty acids, TLR4 protein is translocated to
lipid containing rafts where the association to adaptor proteins and membrane assembly
take place. Our collaborators in this study have shown via direct evidence that SsnB
disrupts TLR4 activation and can be a potent TLR4 antagonist. To show the mechanistic
insight of SsnB action in steatohepatitic liver injury, we studied the TLR4 trafficking into
lipid rafts and its disruption by SsnB. Results showed that SsnB administration
significantly decreased the colocalization of TLR4 (red) and lipid raft component flotillin
(green) in the plasma membrane of SH mice (Figure 3.5A). The number of colocalization
events/microscopic field were significantly decreased in SsnB treated group as compared
to SH mice livers (Figure 3.5 B)(P<0.05). The results suggested that SsnB has a
significant role in TLR4 trafficking in early steatohepatitic injury and the modulation of
TLR4 trafficking might be contributing in part for the attenuation of inflammation seen
with SsnB administration. Since resident macrophages play a clear role in liver
inflammation in NASH, we studied the TLR4 trafficking in immortalized Kupffer cells
following their stimulation with LPS, the classical ligand of TLR4. Results showed that
incubation of Kupffer cells with LPS (50ng/ml) significantly increased colocalization of
TLR4 with lipid raft marker flotillin while co-incubation with SsnB (100µg/ml)
significantly attenuated the TLR4 translocation to the rafts (Figure. 3.6A and B). The
SsnB co-incubation resulted in a 3 fold decrease in the colocalization events (Figure. 3.6
B(P<0.05). The colocalization is also shown in higher magnification (Figure. 3.6C)
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SsnB targets leptin induced TLR4 trafficking in Kupffer cells. We have shown
previously that proinflammatory adipokine leptin regulates Kupffer cell activation via
reactive oxygen species generation(40). Leptin increased peroxynitrite generation by
increasing NADPH oxidase activation that resulted in higher inflammatory mediation.
Since hepatic leptin resistance is a common phenomenon in NASH patients, and
selective leptin signaling observed in hepatic stellate cells, we studied the role of leptin in
TLR4 trafficking to the lipid rafts in vitro(112, 113). Results showed that leptin
administration to immortalized Kupffer cell culture significantly increased the TLR4Flotillin colocalization as evidenced by yellow spots on the membranes of the incubated
cells (Figure 3.7A-40x and C-60x oil images showing clusters of cells with colocalization
in the membranes). Analysis of the number of colocalization events showed a significant
increase in leptin-treated group when compared to cell-only controls (Figure 3.7A and
B)(P<0.05) with a 4 fold increase recorded in this group. SsnB co-incubation with leptin
significantly decreased the colocalization events in these cells (Figure 3.7A and B)
(P<0.05). The results suggested that similar to LPS, TLR4 trafficking to the lipid rafts
was also influenced by leptin, a proinflammatory adipokine with known effects in NASH.
Though the mechanism of leptin action via TLR4 ligand binding is highly unlikely in
these cells, SsnB modulation of leptin might be an upstream event and can be a common
target for SsnB apart from being a strong antagonist for TLR4 activation.
SsnB attenuates NADPH oxidase activation and peroxynitrite generation. Since
SsnB administration significantly decreased TLR4-induced hepatic inflammation in
obesity both in response to LPS and leptin, we argued about the presence of a significant
target upstream of the TLR4 pathway that might be common and conspicuous for both
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leptin and LPS mediated signaling. We recently showed that TLR4-lipid raft trafficking
in NASH was mediated by peroxynitrite generated by the activation of NADPH
oxidase(111). To show that SsnB modulated NADPH oxidase activation and
peroxynitrite generation, events that are upstream of TLR4 activation, colocalization
analysis of NADPH oxidase membrane subunits in the membranes of liver tissue were
studied by immunofluorescence microscopy. Results showed that p47 phox (green), a
cytoplasmic subunit required for NADPH oxidase activation colocalized with gp91 (red)
a membrane subunit in liver tissue (Figure 3.8A-20x and C-60x oil images showing
colocalization clusters). Analysis of the number of colocalization events in the liver tissue
showed a significant increase in SH treated group while SsnB treated mice liver showed a
significant decrease in the colocalization events suggesting a decreased NADPH oxidase
activation (Figure 3.8B)(P<0.05). Kupffer cells treated with both leptin and LPS showed
a marked increase in the gp91/p47 phox colocalization events while administration of
SsnB (100 µg/ml) resulted in a significant decrease of the events (Figure 3.8D). Since
NADPH oxidase activation resulted in generation of peroxynitrite in NASH, we
examined the formation of 3-Nitrotyrosine, a marker for peroxynitrite generation in the
diseased liver and immortalized Kupffer cells. Results showed that 3-nitrotyrosine
immunoreactivity as analyzed by immunohistochemistry was significantly increased in
SH mice livers as compared to S only group (Figure 3.9A and B)(P<0.05). SsnB
administered mice livers showed a significant decrease in the 3-nitrotyrosine
immunoreactivity when compared to SH mice livers (Figure 3.9A and B)(P<0.05). Since
peroxynitrite generation requires both O2.- and NO• reactivity in equal diffusion
controlled rates, we studied the release of NO• from the Kupffer cell supernatants
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incubated with both leptin, LPS and SsnB. Results showed that LPS and Leptin
significantly increased NO• release while co-incubation with SsnB significantly
attenuated the release of NO• analyzed by Greiss assay (Figure 3.9C)(P<0.05). The
results suggested that apart from the strong TLR4 pathway antagonism function of SsnB,
it also plays a significant role in NADPH oxidase activation and NO• release in
inflammation. The SsnB attenuation of TLR4 pathway might be in part related to its
effect on NADPH oxidase activation that is upstream of TLR4 trafficking to lipid rafts.
SsnB attenuates TLR ligand-induced gene expression of inflammatory cytokines,
p47 phox, CD68 and cytokine release in mouse primary hepatic macrophages. To
see the direct effect of SsnB on mouse primary hepatic macrophages, qRT PCR was
performed to measure the pro-inflammatory cytokine gene expression levels. Result
showed that as expected, mRNA expression of IL1β, MCP1 and TNFα pro-inflammatory
cytokine gene expression were significantly elevated in LPS treated cells compared to
untreated control cells. However, co-incubation of LPS treated cells with SsnB, decreases
the expression of these genes significantly compared to only LPS treated cells (Figure
3.10A). In another set of experiments, after the mice primary hepatic macrophages were
treated with SsnB and LPS for 24 h, the supernatant was collected for measurement of
TNFα cytokine concentration by ELISA. As shown in Figure 3.10B, in TNFα level in the
control media was almost undetectable. LPS (50 ng/ml) treatment dramatically increased
the TNFα cytokine level. However, co-incubation with SsnB significantly reduced the
TNFα cytokine level (Figure 3.10B). We have shown previously in Figure 3.8 and Figure
3.9 that SsnB significantly reduces the formation of peroxynitrite and corresponding
inflammation and Kupffer cell activation by decreasing the co-localization of gp91/p47
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phox and thus attenuates NADPH oxidase activation. To see whether SsnB has any effect
in attenuating p47phox gene expression, a quantitative-real time PCR was performed to
measure the p47phox gene expression levels. Result showed that mRNA expression of
p47 phox gene expression was significantly elevated in LPS treated cells compared to
untreated control cells (Figure 3.10C). However, co-incubation with SsnB, decreases the
expression of these genes significantly compared to only LPS treated cells.
SsnB treatment does not reduce TLR4 gene expression or protein concentration. To
address the question whether SsnB acts by decreasing TLR4 mRNA expression, qRT
PCR experiments were performed to quantify the TLR4 mRNA expression both invivo
and invitro. Our data shows that SsnB administration may slightly attenuated the upregulation of TLR4 mRNA levels compared to SH group (Figure.3.11A). Co-incubation
of mice primary hepatic macrophages with SsnB also resulted a faint reduction of TLR4
mRNA expression compared to only LPS treated cells (Figure 3.11B). Liang et al., (28)
observed the similar incident and described it as a secondary event to the suppression of
pro-inflammatory signaling pathways. A western blot experiment was also performed
from mice liver homogenates to see if TLR4 protein expression is reduced by SsnB
administration. Our data clearly indicates that SsnB administration didn’t cause any
reduction in total TLR4 protein level (Figure. 3.11C and D). However, it has already been
shown by Liang et al., (28) that SsnB possibly acts by attenuating the interaction of
MyD88 and TLR4 Toll/interleukin-1 receptor (TIR) domain. Our findings also suggest
that SsnB decreases TLR4 trafficking in lipid rafts by preventing NADPH oxidase
activation and reducing nitrative stress. Thus there is a possibility that SsnB induced
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TLR4 signaling attenuation may not be dependent on the total TLR4 protein
concentration.
3.4 DISCUSSION: The present study reports a novel role and mechanistic insight of the
TLR4 antagonist SsnB. Using a rodent model of early steatohepatitic injury, we show
that SsnB attenuated inflammation in the liver by blocking TLR4 trafficking to the lipid
rafts. Further, we deciphered that SsnB could block TLR4 trafficking into the lipid rafts
by decreasing NADPH oxidase activation and peroxynitrite generation. The role of TLR4
in NASH and its consequences is being pursued vigorously across the scientific
community(79, 80, 114). The potent role of TLR4 activation and its downstream
signaling has been reported in both alcoholic and nonalcoholic steatohepatitis(79). In
alcoholic steatohepatitis, portal endotoxemia from gut leaching has been accepted as a
source for the TLR4 ligand in the liver(87, 115). Various studies have reported free fatty
acids and HMGB1 as ligands in TLR4 activation in NASH(95, 116, 117). We recently
reported that peroxynitrite generation activates TLR4 signaling by modulating its
trafficking into the lipid rafts primarily by an upstream NADPH oxidase activation(111).
The results in that study also confirmed an earlier report showing NADPH oxidase as a
prime regulator of TLR4 trafficking but could not provide a molecular mediator for its
actions (95). Interestingly TLR4 downstream signaling is also known to produce NADPH
oxidase activation(118). Our results in this report show a novel role of SsnB, a natural
product derivative in modulating TLR4 trafficking into lipid rafts, a mechanism that
remained elusive before. SsnB has been shown by our collaborators in numerous in vivo
and in vitro studies to be a portent TLR4 antagonist(28, 98-101, 119). SsnB structural
analysis and its characterization in terms of mechanism of action showed that it reduced
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the association of MyD88 with TLR4 and TLR2 but not with TLR9(28). Inflammatory
cytokine signaling emanating from the TLR4 signaling in vitro was specifically blocked
by SsnB while LPS-induced septic shock was reversed by its administration in vivo(101).
Having known the earlier reported mechanisms of SsnB action we explored its role in
NASH induced inflammatory injury. Our rationale was based on the strong inflammatory
phase in NASH that is appreciated in both rodent models of NASH and clinical
phases(120). Our results showed that SsnB administration in vivo reversed inflammatory
pathophysiology primarily evidenced by reduced leukocyte infiltration, decreased
necrosis in Zone3 and lower levels of proinflammatory cytokines IL1β and TNF-α. Since
Kupffer cell activation is a prime inflammatory event in NASH that also has been shown
to play a vital role in activating stellate cells, we examined the levels of CD68 and MCP1. Results showed a dramatic decrease in the levels of the chemokines and surface
expression of CD68. The results were in line with earlier reports from our lab and others
that Kupffer cell activation reversal can have a beneficial effect on NASH progression
and treatment at least in rodent models of NASH(40, 114). The studies reported here
however have not explored the role of SsnB in reversal of Kupffer cell activation since
we knew that SsnB might target TLR4 that has been shown previously to activate
Kupffer cells(121). Though Kupffer cells respond to LPS mediated TLR4 activation,
there are reports of TLR4 expression in hepatocytes, endothelial cells and stellate
cells(79, 90).Interestingly, Kupffer cells are primary foci for generating an inflammatory
response and SsnB action in these cells might mediate the TLR4 activation.. The SsnB
role in preventing TLR4 signaling in Kupffer cells might render a stalling effect on the
initial inflammatory phase which may eventually block stellate cell activation and
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extracellular matrix formation. For the purposes discussed above we used immortalized
Kupffer cells to illustrate the mechanism of SsnB deactivation of TLR4 pathway.
We have recently shown that NASH is characterized by an increase in miR21
induced repression of GRHL3 and SMAD7, two key proteins that have a pronounced role
in sinusoidal endothelial injury and extracellular matrix formation (109, 110).
Interestingly miR21 is a TLR4 inducible non coding RNA and our results in this report of
a significant decrease in miR21-induced repression of PTEN confirmed the SsnB
targeting of TLR4 pathway(58). It will be of interest in later studies, how SsnB may help
in alleviating the miR21-induced repressions of GRHL3 and SMAD 7 in NASH.
To mechanistically explain the role of SsnB in TLR4 deactivation response we
studied the trafficking of TLR4 into lipid rafts which is a prime event in TLR4 activation
and downstream signaling(95). Lipid raft are lipid rich domains within the plasma
membrane that help in assembly of many transmembrane receptors including TLR4(95).
This myriad of molecular events and assembly starts with the binding of an appropriate
ligand to TLR4. We observed that SsnB administration significantly attenuated the
trafficking of TLR4 into lipid rafts as shown by decreased number of colocalization
events (TLR4 and flotillin) in NASH livers. Rat immortalized Kupffer cells were also
used to show the trafficking process and its attenuation by SsnB following TLR
stimulation by LPS. Our results of significant decrease in colocalization events of TLR4
and flotillin in Kupffer cells show that SsnB could exert its TLR4 antagonism by stalling
the lipid raft recruitment process. Though SsnB has been shown by our collaborators to
interfere in the association of TLR4 with its adaptor MyD88, It can be speculated that
SsnB could competitively bind to TLR4 thus restricting the classical ligand LPS to exert
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its effects(28). However this observation is highly speculative at this point since SsnB
binding to TLR4 in NASH has not been studied. Interestingly TLR4 trafficking to rafts
occur on binding of the ligand to TLR4 and it would be interesting to see the molecular
aspects of SsnB binding to TLR4 or its restrictive capacity to alter TLR4 ligand binding
in future studies.
We have shown previously that proinflammatory adipokine leptin mediates the
progression of NASH by activating Kupffer cells, upregulation of non-coding RNAs and
activating pattern recognition receptor P2X7r(109, 110). Leptin has been shown recently
to upregulate TLR2 expression in monocytes (122). Extending the studies of leptin
induced proinflammatory action in Kupffer cells we studied their role in activating TLR4
trafficking in these cells. Results showed that leptin activated TLR4 signaling via
promoting the TLR4 trafficking to lipid rafts an event that was attenuated by SsnB coincubation. These results were significant since it showed that SsnB can target an
upstream molecular event in lipid raft trafficking of TLR4, considering the fact that leptin
is not a ligand for TLR4 neither has it been shown to have structural similarity to a
classical ligand of TLR4. We also have evidence from previous published reports from
our lab that (i) leptin targets NADPH oxidase activation and (ii) NADPH oxidase drives
TLR4 trafficking via peroxynitrite generation (40, 111). Based on these arguments we
conducted studies to show the role of SsnB in NADPH oxidase activation. Our results of
a significant increase in colocalization of gp91 (membrane subunit) and p47 phox
(cytoplasmic subunit) in SH groups and its subsequent decrease in these events following
SsnB administration indicated a novel role of SsnB apart from its proven role as an TLR4
antagonist. Parallel to the in vivo data, Kupffer cells also showed significant attenuation
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of NADPH oxidase activation following SsnB administration in response to both leptin
and LPS. However it needs to be considered that NADPH oxidase activation primarily
depends on membrane assembly of a number of subunits, p47 phox being one of them, a
crucial element for NOX2 type NADPH oxidases(33, 46). Finally, SsnB-induced
decrease in peroxynitrite marker 3-nitrotyrosine both in vivo and nitric oxide release in
vitro showed a clear mechanistic connection between NADPH oxidation, increased
nitrative stress and TLR4 activation following SsnB administration. It is worth
mentioning here that peroxynitrite induced HMGB1, a TLR4 activator release has been
shown(123). A decrease in peroxynitrite formation following NADPH oxidase inhibition
by SsnB might be a parallel mechanism of SsnB amelioration of TLR4 pathway and
subsequent decrease in early steatoheaptitic injury and inflammation in the liver.
Taken together, our data describe a novel mechanistic role of SsnB in resolving
NASH –induced inflammation primarily by blocking TLR4 lipid raft trafficking and
NADPH oxidase activation. Future studies featuring SsnB binding kinetics to TLR4 or
pathways unique to deactivation of NADPH oxidase might usher new light on probable
therapeutic benefits of SsnB.
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Figure 3.1 Sparstolonin B (SsnB) administration attenuates early steatohepatitic injury in
obese mice. A: hematoxylin and eosin-stained paraffin-embedded liver tissue sections of
steatosis (S; i), steatohepatitic injury (SH; ii), and SH+SsnB (iii) mice. Images were taken
at ×10 magnification. B: serum levels of alanine aminotransferase (ALT) from S, SH, and
SH+SsnB groups. *P < 0.05.
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Figure 3.2 SsnB administration to SH mice ameliorates proinflammatory cytokines and
decreases M1 polarization. A: qRT-PCR analysis of mRNA expression of TNF-α, IFN-γ,
IL-1β, and IL-23 from liver homogenates of S, SH, and SH+SsnB mice, normalized
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against S (*P < 0.05). B: TNF-α (top) and IL-1β (bottom) immunoreactivity as shown by
immunohistochemistry in liver slices from S (i), SH (ii), and SH+SsnB (iii) mouse
samples. Images were taken at ×20 magnification. C: morphometric analysis of TNF-α
immunoreactivity in S, SH, and SH+SsnB groups (*P < 0.05). D: morphometric analysis
of IL-1β immunoreactivity in S, SH, and SH+SsnB groups (*P < 0.05).

Figure 3.3 SsnB administration modulates Kupffer cell activation in early steatohepatitic
injury. A:qRT-PCR analysis of mRNA expression of CD68 and monocyte
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chemoattractant protein-1 (MCP1) from liver homogenates of S, SH, and SH+SsnB mice,
normalized against S (*P < 0.05). B: MCP1 (top) and F4/80 (bottom) immunoreactivity
as shown by immunohistochemistry in liver slices from S (i), SH (ii), and SH+SsnB (iii)
mouse samples. Images were taken at ×20 magnification. C: morphometric analysis of
MCP1 immunoreactivity in S, SH, and SH+SsnB groups (*P < 0.05). D: morphometric
analysis of F4/80 immunoreactivity in S, SH, and SH+SsnB groups (*P < 0.05).

Figure 3.4. SsnB administration attenuates miR21 expression and repression of
phosphatase and Tensin homologue (PTEN). A: qRTPCR analysis of miR21 expression
of S, SH, SH+SsnB mice samples normalized against S (*P<0.05). B: Western blot
analysis of β-actin and PTEN protein levels of S, SH, SH+SsnB sample1 and SH+SsnB
sample2 respectively. C: Immunoreactive band analysis of PTEN normalized against βactin. Y-axis depicts the PTEN/actin ratio from S, SH, SH+SsnB sample1 and SH+SsnB
sample2(*P<0.05).
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Figure 3.5 SsnB targets TLR4 trafficking to lipid rafts. A: immunofluorescence dual
labeling depicting TLR4 (red)-flottilin1 (green) colocalization (yellow) in S (i) SH (ii),
and SH+SsnB (iii) liver samples, taken at ×20 magnification. B: morphometric analysis
of colocalization events in A, shown as colocalization events per 3× field (*P < 0.05).
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Figure 3.6 SsnB targets LPS-induced TLR4 trafficking in Kupffer cells. A:
immunofluorescence laser scanning images for colocalization of TLR4 (red) and
flottilin2 (green) in rat Kupffer cells of the control (i–iv), LPS-treated (v–viii), and
LPS+SsnB-treated (ix–xii) groups. Images in overlay panels on right depict
colocalizations of TLR4-flottilin2, as revealed by the yellow regions. Images were taken
at ×40 magnification. B: morphometric analysis of colocalization events in A, shown as
colocalization events per 100 cells (*P < 0.05). C: immunofluorescence dual labeling of
LPS-treated rat Kupffer cell sample depicting TLR4 (red)-flottilin2 (green) colocalization
(yellow) at ×60(oil) magnification.
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Figure 3.7 SsnB targets leptin-induced TLR4 trafficking in Kupffer cells. A:
immunofluorescence laser scanning images for colocalization of TLR4 (red) and
flottilin2 (green) in rat Kupffer cells of the Control (i–iv), leptin-treated (v–viii), and
leptin+SsnB-treated (ix–xii) groups. Images in overlay panels on right depict
colocalizations of TLR4-flottilin2, as revealed by the yellow regions. Images were taken
at ×40 magnification. B: morphometric analysis of colocalization events in A, shown as
colocalization events per 100 cells (*P < 0.05). C: immunofluorescence dual labeling of
leptin-treated rat Kupffer cell sample depicting TLR4 (red)-flottilin2 (green)
colocalization (yellow) taken at ×60(oil) magnification.
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Figure 3.8 SsnB attenuates NADPH oxidase activation. A: immunofluorescence dual
labeling depicting gp91phox (red)-p47phox (green) colocalization (yellow) in S (i), SH
(ii), and SH+SsnB (iii) liver samples, taken at ×20 magnification. B: morphometric
analysis of colocalization events in A, shown as colocalization events per 3× field (*P <
0.05). C: immunofluorescence dual labeling of SH liver sample depicting gp91phox
(red)-p47phox (green) colocalization (yellow) taken at ×60 (oil) magnification. D:
immunofluorescence dual labeling of control (i), LPS (ii), LPS+SsnB (iii), control (iv),
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leptin (v), and leptin+SsnB (vi) rat Kupffer cell samples depicting gp91phox (red)p47phox (green) colocalization (yellow), taken at ×40 magnification.

Figure 3.9 SsnB attenuates NADPH oxidase activation and peroxynitrite generation. A:
3-nitrotyrosine immunoreactivity as shown by immunohistochemistry in liver slices from
S (i), SH (ii), and SH+SsnB (iii) mouse samples. Images were taken at ×20
magnification. B: morphometric analysis of 3-nitrotyrosine immunoreactivity in S, SH,
and SH+SsnB groups (*P < 0.05). C: nitric oxide (nitrite) concentration measured by
nitric oxide colorimetric assay in the supernatant collected from control, LPS-treated, and
LPS+SsnB-treated rat Kupffer cells (*P < 0.05).
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Figure 3.10 SsnB attenuates TLR ligand-induced macrophage activation, gene expression
of P47phox, and gene expression and release of inflammatory cytokines in mouse
primary hepatic macrophages. A: qRT-PCR analysis of mRNA expression of IL-1β,
MCP1, and TNF-α from control (untreated), LPS-treated, and LPS+SsnB-treated mouse
primary hepatic macrophages, normalized against control (*P < 0.05). B: TNF-α cytokine
levels measured by ELISA from the supernatant collected from control, LPS-treated, and
LPS+SsnB-treated mouse primary hepatic macrophages, normalized against control (*P
< 0.05). C: qRT-PCR analysis of mRNA expression of p47phox from control (untreated),
LPS-treated, and LPS+SsnB-treated mouse primary hepatic macrophages, normalized
against
control
(*P
<
0.05).
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Figure 3.11 SsnB treatment does not reduce TLR4 gene expression or protein
concentration. A: qRT-PCR analysis of mRNA expression of TLR4 from liver
homogenates of S, SH, and SH+SsnB mice, normalized against S (*P < 0.05). B: qRTPCR analysis of mRNA expression of TLR4 from control (untreated), LPS-treated, and
LPS+SsnB-treated mouse primary hepatic macrophages, normalized against control (*P
< 0.05). C: Western blot analysis of β-actin and TLR4 protein levels in the liver
homogenates of lean control (LC), LC+bromodichloromethane (BDCM), S, S+SsnB, SH,
and SH+SsnB groups. D: immunoreactive band analysis of TLR4 normalized against βactin. y-Axis depicts the TLR4-to-β-actin ratio for LC, LC+BDCM, S, S+SsnB, SH, and
SH+SsnB
groups.

78

CHAPTER 4
ADMINISTRATION OF SPARSTOLONIN B ATTENUATES HEPATIC
FIBROSIS BY INHIBITING PROLIFERATION AND INDUCING
APOPTOSIS IN HEPATIC STELLATE CELLS.3

3

Dattaroy D, Chandrashekaran V, Seth RK, Alhasson F, Fan D, Nagarkatti M, Nagarkatti
Chatterjee S. To be submitted to British Journal of Pharmacology.
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Abstract:
This research unravels anti-fibrotic and anti-proliferative mechanisms of a plant derived
TLR4 antagonist, Sparstolonin B (SsnB) in a Bromodichloromechane (BDCM) induced
murine model of NASH and hepatic stellate cell culture. SsnB showed a promising role
to lessen liver fibrosis by upregulating cell cycle inhibitory proteins and inhibiting
fibrogenic cell proliferation. Mechanistically, SsnB, a TLR4 antagonist, decreased TLR4PI3k akt signaling by upregulating PTEN protein expression. It also decreased MDM2
protein activation and increased p53 and p21 gene and protein expression. SsnB also
downregulated pro-fibrogenic hedgehog signaling pathway, inhibited hepatic stellate cell
proliferation and induced apoptosis in hepatic stellate cells. This anti-proliferative and
pro-apoptotic properties of SsnB can be instrumental to ameliorate fibrotic lesions in liver
when administered to murine model of NASH.
4.1 INTRODUCTION
Nonalcoholic steatohepatitis (NASH) is manifestation of metabolic syndrome in liver
which arises from hepatic fat accumulation (73). NASH is characterized by steatosis (fat
deposition) in liver along with increased liver inflammation, fibrosis and progressive
endothelial dysfunction, which can lead to cirrhosis and hepatocellular carcinoma (125,
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126). NASH is a silent liver disease and patients generally feel well until they develop
irreversible excessive liver damage. As there is almost no medication available to treat
NASH related excessive liver damage, liver transplant can bring the only hope for
survival-given that there is always a short supply of liver and liver transplant has been a
challenge due to graft rejection, graft steatosis, infection during the transplantation etc.
(127). The mortality of NASH affected patients can also increase by cardio-vascular
damage (128). As obesity is becoming a worldwide epidemic, the prevalence of Non
Alcoholic Fatty Liver Disease (NAFLD) is increasing globally. NAFLD affected liver
can progress into NASH like irreversible liver injury due to hepatic toxicity and imposes
a major public health threat (127). Toll like receptors (TLRs) have been shown to play a
major role in the pathogenesis of NASH and clinical studies show that endotoxemia as a
result of leaky gut in NASH condition, can lead to TLR4 activation (24, 90). Increased
oxidative stress, peroxinitrite formation, HMGB1 protein, Fibrinogen or other DAMPs
(damage associated molecular patterns) associated with liver injury, can also act as
ligands for TLR4 signaling (90). TLR4 activation can lead to increased JNK activation,
which leads to inflammation, fibrosis, insulin resistance and other metabolic
dysregulation during NASH (25). Abrogation of TLR4 trafficking to lipid rafts helps to
decrease inflammation in murine NASH models and had better histological outcomes
(90). As TLR4 activation is a major event that leads to several inflammatory pathway
activations and fibrogenesis, a potent TLR4 antagonist can be useful to treat such
condition. Therefore, development of a novel therapeutic strategy to combat this disease
is needed. In this research, we study the therapeutic role of a novel plant derived
compound, Sparstolonin B (SsnB), on a toxin induced model of nonalcoholic
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steatohepatitis. The purpose of the present study was to investigate the impact of SsnB on
hepatic fibrosis in vivo and in vitro through assessment of the effects of SsnB on the
proliferation of hepatic stellate cells, extracellular matrix deposition and pro-fibrogenic
signaling pathways. We also wanted to find out the effect of SsnB on anti- proliferative
proteins and hedgehog signaling pathway.
4.2 MATERIALS AND METHODS
Cell culture: Human immortalized stellate cell line (LX2) (kindly gifted by Dr. Ana Mae
Diehl, Duke University) was grown in complete Dulbecco’s Modified Eagle’s Medium
(DMEM, Corning, VA) with 10% fetal bovine serum (FBS, Atlas Biologicals, CO) and
1x Penicillin-Streptomycin solution (Gibco, Life Technologies, NY) at 37°C in a
humidified incubator with 5% CO2. Tissue culture plastic wares, HBSS buffer were
purchased from Corning (Corning, VA). Sparstolonin B (SsnB) compound was kindly
gifted by our collaborator Dr. Daping Fan (Cell Biology and Anatomy, University of
South Carolina School of Medicine). Stock solution of SsnB was prepared in 100%
dimethyl sulfoxide (DMSO). The final concentrations of SsnB on cells were 10µg/ml,
0.1% DMSO and 100µg/ml, 0.1% DMSO respectively. The cells were plated on 6
well/12 well plates using DMEM medium supplemented with 10% FBS. Before treating
the cells with LPS (100ng/ml) and SsnB (10μM, 100μM), cells were cultured in DMEM
with 2% FBS (overnight). All treatments are given for 24 hours in 2% FBS containing
DMEM medium. Cells treated with 0.1% DMSO were used as control. Primary rat
hepatic stellate cells (ScienCell Research Lab, Carlsbad, CA) were cultured in specific
medium as instructed by the manufacturer, on poly-l-lysine (ScienCell Research Lab)coated 6well/ 12-well plates and incubated at 37°C in a humidified incubator with 5%
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CO2 to initiate the culture. Treatments of LPS and SsnB were given as discussed above.
All treated cells were subjected to mRNA and protein extraction. Maintaining
aforementioned conditions, cells were plated on coverslips by putting coverslips on each
well of 12 well plates and the cells adhered on coverslips were used for immunefluorescence dual labelling staining after the treatment.
Mouse Models: Pathogen-free, male mice with C57BL/6J background (Jackson
Laboratories, Bar Harbor, ME) were housed one per cage at 23-24°C with a 12-h/12-h
light/dark cycle at libitum access to food and water. They were fed with 60% kcal high
fat diet (Research Diets, New Brunswick, NJ) from 6 weeks until 16 weeks to generate a
model of steatosis. We refer to this group as Control. A similar group of high fat fed mice
were administered Bromodichloromethane BDCM (1mmol/kg, diluted in corn oil) though
intraperitoneal injection, twice a week for 1 month to generate BDCM induced Nonalcoholic steatohepatitis model of mice (NASH). BDCM and corn oil were purchased
from Sigma-Aldrich (St. Louis, MO). A group of NASH mice were administered with
SsnB (3mg/kg) intraperitoneally twice for 4 weeks (NASH+SsnB). NIH guideline for
Humane Care and Use of Laboratory Animals and local IACUC standards were followed
during animal handling. Animal experiments were approved by the University of South
Carolina at Columbia. Upon completion of the treatment, all mice were sacrificed for
liver tissues and serum samples for further experiments.
Laboratory analysis
Picrosirius red staining: Picrosirius red staining of formalin-fixed, paraffin embedded
liver tissue sections (5-μm-thick) was done using a Nova ultra-sirius red stain kit
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following manufacturer's instructions (IHC-World). Liver sections were observed under a
×20 objective of a light microscope. Morphometric analysis of the stained regions of the
tissue sections was performed using cellSens software (Olympus). The degree of fibrosis
was evaluated by following the METAVIR scoring system (F0: no fibrosis, F1: portal
fibrosis without septum formation, F2: portal fibrosis with few septum formation, F3:
portal fibrosis with several septum formations but no cirrhosis and F4: cirrhosis) on the
basis of histological observation of the slides.
Immunohistochemistry: Formalin-fixed, paraffin embedded liver tissue sections (5-μmthick) were subjected to de-paraffinization and antigen retrieval using standard protocol.
Immunohistochemistry was performed on neutral buffer formalin (NBF) fixed liver
tissues according to the protocol described in our early publication (19). Mouse
monoclonal p53 (Cell Signaling Technology, MA) and p21 antibody (Santa cruz
Biotechnology, TX) were used in recommended dilution. Rest of the experiment was
processed as described in our previous publication (19).
Immunofluorescence Microscopy
In vivo: De-paraffinization and antigen retrieval was performed on formalin-fixed;
paraffin embedded liver tissue sections (5-μm-thick) were done by using standard
protocol. The primary antibodies MDM2 (Santa cruz Biotechnology, TX), Gli1 (Abcam,
MA) were used in recommended dilutions. Species-specific secondary antibodies
conjugated with Alexa Fluor 633 (Invitrogen, CA) were used against the appropriate
primary antibodies. Rest of the experiment was processed as described in our previous
publication (19).
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In vitro: After completion of the treatments as previously stated, the cell attached
coverslips were fixed and processed according to our previous publication (19). Cells
were incubated with αSMA (Abcam, MA), p53 (CST, Danvers MA), and p21 (Santa cruz
Biotechnology, TX) primary antibodies followed by species-specific Alexa Fluor 633 and
488 (described above), for immunofluorescence dual-labeling staining. Alexa Fluor 633
was used against p53 and p21 antibodies. Alexa Fluor 488 was used against αSMA
antibody. ProLong Gold antifade reagent with DAPI (Life Technologies) was used to
mount the stained cells attached on the coverslips and viewed under ×20 objective with
an Olympus BX51 microscope.
Quantitative Real-Time Polymerase Chain Reaction: Gene expression (mRNA) levels
of rat hepatic stellate cell samples were measured by quantitative real-time reverse
transcription-polymerase chain reaction (qRT-PCR) by following our routine lab
protocol. The primers used for Real time PCR in 5’to 3’ orientations are rat p53
(Forward: GCACGGCCTTTGTGGTAAAA,Reverse: TTTGCCAGGGCTGAGTAACC)
ratp21(Forward:TGCCTTAGCCTTCATTCAGTGT,Reverse:TATCGAATTGCACGAG
GGGAG).The primers used for Real time PCR in 5’to 3’ orientations for LX2 cells are
humanGli1(Forward:GGCTCGCCATAGCTACTGAT,Reverse:CCAGCGCCCAGACA
GAG),humanGli2(Forward:AGTTAATGAGAACCTGGGCAGT,Reverse:TTGGCAAA
GGCGGGATAGTC),humanIHH(Forward:CAGCCTGCTCTCACTACGAG,

Reverse:

CCCAAAGGGGCCTAAGATGG),humanPtc(Forward:GGGTGGCACAGTCAAGAAC
AG, Reverse: TACCCCTTGAAGTGCTCGTACA). miR21 levels in tissues were
measured as described in chapter2.
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Western Blotting: Protein extraction and western blot from in vivo and in vitro samples
were performed according to our lab protocol described elsewhere (129). Primary
antibodies PTEN, β actin (Abcam, MA), p53 (Cell Signaling Technology, MA), Cyclin
E, cleaved caspase3, total caspase3 and cleaved PARP1(Santa cruz Biotechnology, TX)
were used at recommended dilutions, and compatible horseradish peroxidase-conjugated
secondary antibodies were used.
TUNEL assay: TUNEL based ApopTag® technology (EMD Millipore, MO) was used
to detect apoptotic cells according to the manufacturer’s instructions. ProLong Gold
Antifade Reagent (Life Technologies, Carlsbad, CA) with DAPI was used to mount the
coverslips. The cells were imaged using immunofluorescence microscopy under ×20
objective.
Cell cycle analysis: After treating LX2 cells with LPS and/ SsnB (as described
previously), the cells harvested and centrifuged for 10 minutes at 1000 rpm at 25°C in the
medium. After aspirating the medium, cells were washed with PBS and again centrifuged
for 10 minutes at 1000 rpm at 25°C. This step was repeated again and the cells were fixed
with 70% ice cold ethanol (dropwise) for 30 minutes on ice. After fixing the cells, they
were centrifuged again at 1000rpm for 5 minutes. Ethanol was aspirated and 1 ml of
propidium iodide solution (containing RNase A and 0.1%Triton X) was added to the
pellets and incubated in ice for 30 minutes on ice. The samples were analyzed by
Beckman Coulter FC500 Flow Cytometer at Institutional Resource Facility at the
University Of South Carolina School of Medicine.
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Statistics: Data were represented as mean ± S.E. Statistical significance was calculated
by Student's t test and the graphs were plotted using Origin (OriginLab Corporation,
MA). p ≤ 0.05 was considered statistically significant.
4.3 RESULTS:
SsnB treatment ameliorates liver fibrosis in NASH mice. Picrosirius red stain is
widely used to stain extracellular collagen matrix to detect fibrotic scar deposition in
tissues. This staining is based on the firm binding of this stain’s sulfonic acid groups with
the basic moieties of collagen fibers. Histological evaluation of mice liver tissues in
NASH group shows increase deposition of collagen matrix and fibrosis compared to
Control group. SsnB treated group (NASH+SsnB) showed significant reduction of
fibrosis (Figure 4.1A, B). In Control group fibrosis scoring was F0 (no fibrosis), NASH
group the fibrosis grade was F2 to F3 (periportal and septal fibrosis). Interestingly, fibrosis
scoring in NASH+SsnB group was F0 to F1 (no fibrosis to mild fibrosis without septa)
(Figure 4.1C).
SsnB treatment decreased microRNA21 expression and upregulated PTEN protein
expression in NASH liver. MicroRNA21 (miR21) is known to downregulate tumor
suppressor protein PTEN (130). We have previously shown that SsnB administration
decreases miR21 expression and induces PTEN expression in an early NASH model
where diet induced obese mice were subjected to BDCM treatment for 1 week (19).
Interestingly, we observed similar characteristics of SsnB when it was administered in
our full-blown NASH model where diet induced obese mice were subjected to BDCM
treatment for 4 weeks. We found that, SsnB treatment (NASH+SsnB group) significantly
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reduces miR21 expression compared to NASH group (Figure 4.2 A). PTEN protein
expression was decreased in NASH group compared to Control. However, SsnB
treatment (NASH+SsnB) augmented PTEN expression (Figure 4.2 B) which
complemented the reduced expression of miR21 in that group.
SsnB treatment induced PTEN expression increases p53, p21 upregulation and
decreases hedgehog signaling in liver. To detect the possible mechanism of PTEN
induced expression of p53, we measured the immunoreactivity of MDM2 in paraffin
embedded liver tissue sections though immunofluorescence microscopy. We observed
significantly increased immunoreactivity of MDM2 in NASH liver section compared to
Control liver. SsnB treated (NASH+SsnB) liver showed considerable decrease in MDM2
immunoreactivity compared to NASH liver (Figure 4.3A). MDM2 is a known inhibitor of
p53. Interestingly, Immunohistochemistry against p53 revealed decreased p53 protein
expression in NASH mice liver in the sinusoidal area which was augmented with SsnB
treatment (NASH+SsnB) (Figure 4.3B). Immunohistochemistry against p21 also reveals
significant decrease in p21 immunoreactivity in NASH liver compared to Control. SsnB
treatment significantly increased p21 immunoreactivity in the sinusoidal area of liver in
NASH+SsnB

group

compared

to

NASH

group

(Figure

4.3C).

Moreover,

immunoreactivity against Gli1, a pro-fibrogenic nuclear transcription factor, was
significantly increased in NASH liver section compared to Control liver. SsnB treated
(NASH+SsnB) liver showed remarkable decrease in Gli1 immunoreactivity compared to
NASH liver –as observed by immunofluorescence microscopy (Figure 4.3D).
SsnB treatment decreased p53, p21 expression in vitro. To see whether SsnB can
reduce expression of p53 and p21 in vitro as it does in vivo, we measured gene expression
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of p53 and p21 through qRT PCR experiments in primary rat hepatic stellate cells. LPS
treatment increased the gene expression of p53 and p21 compared to untreated or control
cells. However, SsnB treatment was able to repress LPS induced upregulation of those
genes (Figure 4.4A). Immunofluorescence microscopy also revealed increased
immunoreactivity of p53 and p21 in SsnB treated primary rat hepatic stellate cells
(LPS+SsnB) compared to only LPS treatment (Figure 4.4B, C respectively).
SsnB treatment decreased gene expression of hedgehog signaling markers and
reduces Cyclin E protein expression in vitro. To correlate SsnB induced repression of
Gli1 (a hedgehog transcription factor) in vivo in an in vitro model, we measured gene
expression of hedgehog signaling specific markers through qRT PCR experiments. LPS
treatment increased the gene expression of Gli1, Gli2, Indian hedgehog (IHH) and
Patched (Ptc) compared to untreated or control cells. However, SsnB treatment was able
to repress LPS induced upregulation of those genes (Figure 4.5A). To see whether SsnB
upregulation of PTEN, p53, p21 and repression of Gli1 alters proliferation of activated
HSCs, we measured Cyclin E protein level from cell homogenates. LPS treatment had
increased Cyclin E level compared to Control which decreased upon SsnB treatment
(Figure 4.5B).
SsnB treatment decreases proliferation and induces apoptosis in hepatic stellate
cells. We performed flow cytometry to evaluate the effect of SsnB on hepatic stellate cell
cycle progression. After treating the LX2 cells with vehicle, LPS and/ SsnB for 24 hours
(as described previously), the cells were collected and stained with propidium iodide and
then analyzed by Beckman Coulter FC500 Flow Cytometer. The resulting data clearly
demonstrates that treatment of LX2 cells with SsnB (both 10 and 100μM concentrations)
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induced accumulation of cells in G2/M phase (38.14% and 36.75% in SsnB 10μM and
100μM respectively) compared to LPS treated group (27.55%) accompanied by a
decreased number of cells in the G0-G1 phase (Figure 4.6 A). We also observed higher
number of apoptotic nuclei in SsnB treated cells (LPS+SsnB) (Figure 4.6B). Western blot
data clearly reveals increased p53 accumulation, increased cleaved caspase3 and cleaved
PARP1 proteins in SsnB treated LX2 cells compared to LPS treated and control cells
(Figure 4.6C), further establishing the pro-apoptotic role of SsnB.
4.4 DISCUSSION:
This study shows the anti-fibrotic and anti-proliferative mechanisms of plant derived
TLR4 antagonist, Sparstolonin B (SsnB). Mechanistically, SsnB reduces TLR signaling
by inhibiting MyD88 recruitment to TLR4 (28). Our initial histochemical data from
picrosirius red stained liver slices proved that SsnB prevents NASH induced fibrotic
scars. We wanted to explore whether SsnB inhibits fibrosis through inhibiting TLR4
dependent pro-fibrogenic pathways. It is known that TLR4 signaling pathway activation
can upregulate miR21 (131) which was reversed by SsnB, a TLR4 antagonist. PTEN
(phosphatase and tensin homolog deleted on chromosome ten) is known to be a tumor
suppressor.

It

can

also

inhibit

PI3K/Akt

signaling

by

dephosphorylating

phosphatidylInositol (3,4,5) -trisphosphate (PIP3) at position 3 and also known to be
involved in cell motility, proliferation, survival, metabolism and cellular architecture. It is
known that PTEN can down regulate TLR4 induced pro-inflammatory pathways (132).
Micro-RNA 21 is a known inhibitor of PTEN. Our study shows that PTEN expression is
augmented in SsnB treated samples where miR21 was also downregulated. This proves
that, SsnB can upregulate PTEN expression by inhibiting TLR4 induced miR21
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expression in our NASH model. It is known that activated TLR4-PI3K pathway can
induce p53 degradation by upregulating MDM2 (133). Recent research shows that
senescence induction in fibrogenic cells by increasing p21, p53 can help to reduce
excessive fibroblast proliferation and suppress hepatic tumor (134). However, no research
has focused on the possible route of repressing hepatic stellate cell proliferation by
antagonizing TLR4-PI3K/Akt-MDM2 signaling pathway by SsnB. We found that SsnB,
a TLR4 antagonist can possibly affect TLR4-PI3K/Akt signaling by upregulating PTEN
protein expression. Our data suggested that SsnB treatment downregulated MDM2 which
was otherwise activated in NASH liver. Interestingly, we found that, p53 was upregulated
in SsnB treatment, which proves that SsnB induced p53 activation by suppressing MDM2
in a PTEN dependent mechanism (135). We also found upregulated p21 protein
expression in SsnB treated liver (NASH+SsnB) compared to NASH liver. It is known
that increased p53 induces p21 expression (136) which further supports our findings.
Induction of p53 and p21 in fibrotic liver can be instrumental to decrease uncontrolled
proliferation of fibroblasts. As uncontrolled HSC (a hepatic fibroblast) proliferation plays
a major factor in hepatic fibrogenesis, we wanted to see whether SsnB induced activation
of p53, p21 and decreased the proliferation of activated stellate cells. In vitro results
showed that SsnB treatment increases mRNA and protein levels of p53 and p21 in HSC
which was otherwise repressed by LPS-proving the anti-proliferative effect of SsnB.
Hedgehog signaling plays a key role in liver fibrosis and is an important therapeutic
target of anti-fibrotic drugs (137). Glioma-associated oncogene homolog1 (Gli1) is a
transcription factor which is a downstream target of hedgehog signaling pathway (138).
Previous research has shown that increased p53 expression is known to inhibit Gli1
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(139).We found that SsnB treated mice liver tissue (NASH+SsnB) having upregulated
p53 protein expression also had reduced expression of Gli1 compared to NASH mice
liver. Activation of hepatic stellate cells (HSC) induces fibrosis in the liver and
suppression of Hedgehog signaling in these cells is known to inhibit HSC activation
(140).We found that SsnB treatment in HSC culture downregulates LPS induced
activation of Hedgehog signal specific gene expression.
Hedgehog signaling pathway is known to induce proliferation by upregulating
Cyclin D and Cyclin E. Shh proliferative signaling stimulates or maintain cyclin gene
expression and activity of the G1cyclin-Rb axis in proliferating cells (141, 142). Gli1
inhibition is also known to inhibit cell growth and cell cycle progression at G2/M phase
and induced apoptosis (143). Several researchers have already shown that SsnB can
inhibit angiogenesis and proliferation of cancer cells by inhibiting mitotic cyclins (104,
136). Similarly, our study found that SsnB treatment decreased Cyclin E activation in
hepatic stellate cells. We also observed SsnB induced suppression of stellate cell
proliferation at G2/M phase of cell cycle and apoptosis of hepatic stellate cells. Apoptosis
induction in activated HSCs is one important therapeutic target to decrease HSC
proliferation and hepatic fibrosis (144). Anti-apoptotic role of SsnB has previously been
shown in different cell types (103). We observed significant number of apoptotic cells in
SsnB treated group (LPS+SsnB) compared to untreated cells and LPS treated cells.
Inhibition of hepatic stellate cell proliferation can reduce liver fibrosis and is a major
therapeutic target of anti-fibrotic drugs (145, 146). Anti-proliferative and pro-apoptotic
properties of SsnB make it a potential antifibrotic molecule. As In future, it will be
interesting to see therapeutic role of SsnB in other in vivo models of liver fibrosis. Apart
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from HSCs, portal fibroblasts and mesothelial cells are also known to be precursors of
myofibroblasts. Hepatic cholangiocytes and hepatocytes can also acquire phenotype of
myofibroblasts through a process of epithelial to mesenchymal transition in the liver
(147, 148). It is important to elucidate the cell specific anti-fibrotic mechanisms of SsnB
in future studies.
In conclusion, SsnB inhibited liver fibrosis in murine NASH model and in HSC
culture by modulating the expression of cell cycle related proteins and by downregulating
the Hedgehog signaling pathway. These results suggest that SsnB is a promising
compound to attenuate liver fibrogenesis.
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Figure 4.1 SsnB treatment ameliorates liver fibrosis in NASH mice. A: Representative
images of picrisirius red stain of Control, NASH and NASH+SsnB mice. Images were
taken at ×20 magnification. (*P < 0.05). B: Morphometric analysis of picrosirius red
immunohistochemistry in liver slices from Control, NASH and NASH+SsnB mice
groups. (*P < 0.05). C: The degree of fibrosis by METAVIR scoring system. (*p<0.05).
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Figure 4.2 SsnB treatment decreased microRNA21 expression and upregulated PTEN
protein expression in NASH liver. A: qRT-PCR analysis of miR21 expression of Control,
NASH, and NASH+SsnB mouse liver samples normalized against Control (*P < 0.05).
B: Western blot analysis of β-actin and PTEN protein levels of Control, NASH, and
NASH+SsnB liver homogenates.
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Figure 4.3 SsnB treatment induced PTEN expression increases p53, p21 upregulation and
decreases hedgehog signaling in liver. A: Representative images of MDM2
immunoreactivity as shown by immunofluorescence microscopy on liver slices of
Control, NASH and NASH+SsnB mice, taken at ×20 magnification using
immunofluorescence microscopy. B: Representative images of p53 immunoreactivity as
shown by immunohistochemistry on liver slices of Control, NASH and NASH+SsnB
mice, taken at ×20 magnification.
C: Representative images of p21
immunohistochemistry on liver slices of Control, NASH and NASH+SsnB mice, taken at
×20 magnification. D: Representative images of Gli1 immunoreactivity as shown by
immunofluorescence microscopy on liver slices of Control, NASH and NASH+SsnB
mice, taken at ×20 magnification using immunofluorescence microscopy.
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Figure 4.4 SsnB treatment decreased p53, p21 expression in vitro. A: qRT-PCR analysis
of mRNA expression of p53 and p21 from control (untreated), LPS-treated, and
LPS+SsnB(100μM) treated rat primary hepatic stellate cells, normalized against control
(*P < 0.05). B. Immunofluorescence dual labeling of Control (untreated), LPS-treated,
and LPS+SsnB(100μM) treated rat primary hepatic stellate cells depicting αSMA(green)-p53 (red) co-localization (yellow), taken at ×20 magnification. C.
Immunoreactivity of p21 (red) in control (untreated), LPS-treated, and
LPS+SsnB(100μM) treated rat primary hepatic stellate as shown by immunofluorescence
microscopy at ×20 magnification.
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Figure 4.5 SsnB treatment decreased gene expression of hedgehog signaling markers and
reduces Cyclin E protein expression in vitro. A: qRT-PCR analysis of mRNA expression
of Gli1, Gli2, IHH, Ptc from Control (untreated), LPS-treated, and LPS+SsnB(10μM
/100μM) treated human immortalized hepatic stellate cells (LX2), normalized against
control (*P < 0.05). B: Western blot analysis of Cyclin E and β-actin protein levels of
Control (untreated), LPS-treated, and LPS+SsnB(100μM) treated human immortalized
hepatic stellate cells (LX2).
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Figure 4.6 SsnB treatment decreases proliferation and induces apoptosis in hepatic
stellate cells. A: Cell cycle analysis of untreated cells (control), cells treated with LPS
and LPS+SsnB (10/100μM) Quantitation of the PI staining data is presented as the cell
cycle distribution percentages. B: Apoptosis is indicated by TUNEL based ApopTag®
technology (EMD Millipore, MO) which labels 3’-OH ends of DNA fragments by
fluorescent antibody as detected by immunofluorescence microscopy in Control
(untreated), LPS-treated, and LPS+SsnB(100μM) treated LX2 cells. C: Western blot
analysis of p53,cleaved caspase3, total caspase3, cleaved PARP1 and β-actin protein
levels of Control (untreated), LPS-treated, and LPS+SsnB(10/100μM) treated LX2 cells.
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CHAPTER 5
ADMINISTRATION OF SPARSTOLONIN B ATTENUATES HEPATIC
FIBROSIS BY INHIBITING TGFβ SIGNALING, STAT3 ACTIVATION
AND BY MODULATING HEPATIC STELLATE CELL MORPHOLOGY
IN NASH.4

4

Dattaroy D, Chandrashekaran V, Seth RK, Alhasson F, Fan D, Nagarkatti M, Nagarkatti
Chatterjee S. To be submitted to Journal of Pharmacology and Experimental
Therapeutics.
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Abstract:
Chronic hepatic inflammation can induce hepatic fibrosis and anti-fibrotic drug discovery
is one of the major focuses to treat the pathogenesis of nonalcoholic steatohepatitis
(NASH). We have previously shown that TLR4 activation increases inflammation and
fibrosis in NASH. We have also observed anti-fibrotic and anti-proliferative activity of
Sparstolonin B (SsnB). By using Bromodichloromethane (BDCM) induced model of
NASH and a preventive model where mice having NASH were treated with SsnB, we
aim to explore an alternative molecular mechanism through which SsnB can decrease
fibrosis by antagonizing TLR4 induced TGFβ signaling pathway. Mechanistically, SsnB
augmented BAMBI (a TGFβ pseudo-receptor) expression in mice liver by inhibiting
TLR4 signaling pathway and thus reduced TGFβ signaling, resulting in decreased hepatic
stellate cell activation and extracellular matrix deposition. In vitro experiments on hepatic
stellate cells showed that SsnB increased gene and protein expression of BAMBI. It also
decreased nuclear co-localization of phospho SMAD2/3 and SMAD4 protein and thus
attenuated TGFβ signaling in vitro. We also observed a significant decrease in
phosphorylation of SMAD2/3 protein, decreased STAT3 activation, alteration of focal
adhesion protein and stress fiber disassembly upon SsnB administration in hepatic stellate
cells which further confirms the antagonistic effect of SsnB on fibrogenesis.
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5.1 INTRODUCTION:
Nonalcoholic steatohepatitis (NASH) is a significant cause of mortality as it can cause
liver fibrosis, cirrhosis, portal hypertension, and hepatocellular carcinoma (149-151).
During NASH associated chronic liver inflammation, activated hepatic stellate cells
(HSCs) deposits excessive extracellular matrix proteins in the liver resulting in fibrotic
scars (152). However, there is no therapy available to treat liver fibrosis in the patients
with NASH except some life style modifications (153). Thus it is important to understand
the molecular mechanisms of hepatic fibrosis to design therapeutic strategies to prevent
and treat liver fibrosis. Different inflammatory signaling pathways are pivotal mediators
of liver fibrogenesis and control the transition of quiescent hepatic stellate cells (HSC) to
collagen-secreting myofibroblasts (154). Systemic levels of endotoxins have been
detected in patients with liver cirrhosis (lipopolysaccharide, LPS) (155). Systemic
endotoxins can be recognized by Toll like receptor 4 (TLR4) present in hepatocytes,
kupffer cells, stellate cells, sinusoidal endothelial cells, biliary epithelial cells in the liver
(156). Upon detecting the LPS or pathogen associated molecular patterns (PAMPS), the
TLR4 receptors give rise to a myriad of inflammatory signaling pathways and increase
the production of inflammatory cytokines, induce macrophage infiltration and increase
oxidative stress (156-158). Recent studies have indicated that tissue injury and matrix
degradation can release some endogenous ligands also referred to as damaged associated
molecular patterns (DAMPS) which can activate TLR4 signaling. Injured liver has
augmented expression of TLR4 and its co-receptors which makes it more sensitive to the
cascade of inflammatory cell signaling pathway mediated by TLR4 signaling in the
damaged tissue (27). Induced TLR4 signaling can give rise to different downstream
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factors like pro-inflammatory cytokines, chemotactic cytokines, reactive oxygen species
(ROS), adhesion molecules, cell cycle regulating proteins, TGF-β1 pseudoreceptor
BAMBI-which can give rise to pro-fibrogenic signals. Hepatic stellate cells along with
kupffer cells, may be a target for TLR4 ligand induced liver injury and offer a direct
connection

between

inflammatory

and

fibrotic

liver

damage

(27).

In

our

Bromodichloromethane (BDCM) induced model of NASH, we have previously shown
that, activation of NADPH oxidase induces Toll like receptor 4 (TLR4) recruitment to the
lipid rafts and thus potentiates inflammation (24). We have also shown that
environmentally relevant doses of Bromodichloromethane (BDCM), induces fibrogenesis
by a NADPH oxidase dependent pathway which increases microRNA21 activation,
hepatic stellate cell activation and accelerates TGFβ signaling (20).
Our collaborators have characterized a plant derived compound Sparstolonin B
(SsnB) as a TLR4 antagonist. SsnB has also been shown to have anti-inflammatory, antiangiogenic, anti-proliferative and anti-oxidant properties (99, 102-104). We have already
shown that SsnB decreases oxidative stress, kupffer cell activation, cytokine production
and macrophage infiltration in an early model of NASH (19).
In this study we test the hypothesis that administration of SsnB in NASH,
abrogates TGFβ signaling and fibrogenesis by upregulating BAMBI in hepatic stellate
cells. As TGFβ signaling activation can also induce JAK-STAT pathway and upregulates
stress fiber assembly in myofibroblasts, we investigated the role of SsnB in alteration of
those pathways (159, 160). In this study, we used a rodent model of NASH in
Bromodichloromethane induced oxidative stress, lipotoxicity, and inflammation were
used as “second/multiple hits” to cause NASH. We also used rat primary hepatic stellate
103

cells and human transformed hepatic stellate cells (LX2) as our in vitro models. Our data
shows that SsnB can decrease myofibroblast proliferation through modulating multiple
signaling pathways.
5.2 MATERIALS AND METHODS:
Cell culture: Human immortalized stellate cell line (LX2) and rat primary hepatic
stellate cells were cultured as described in the previous chapter.
Mouse Models: Pathogen-free, male mice with C57BL/6J background were treated as
described in the previous chapter.
Laboratory analysis
Immunohistochemistry: Immunohistochemistry on formalin-fixed, paraffin embedded
liver tissue sections (5-μm-thick) was performed as described in the previous chapter.
Antibodies against fibronectin, BAMBI (Abcam, MA) were used in recommended
dilution. Morphometric analysis of the immunoreactivity of tissue sections was
performed using cellSens software (Olympus).
Immunofluorescence
In vivo: Formalin-fixed; paraffin embedded liver tissue sections (5-μm-thick) were
processed as mentioned in the previous chapter. The primary antibodies against SMAD4
(Santa cruz Biotechnology, TX), SMAD2/3, αSMA (Abcam, MA) were used in
recommended dilutions. Species-specific secondary antibodies conjugated with Alexa
Fluor 488 (Invitrogen, CA) were used against α-SMA and SMAD4 antibodies and
secondary antibody conjugated with Alexa Fluor 633 was used against SMAD2/3 in
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recommended dilutions. Rest of the experiments was performed as described elsewhere
(17).
In vitro: Cells were incubated with p-SMAD2/3 (Abcam, MA) and SMAD4 (Santa cruz
Biotechnology, TX) primary antibodies followed by species-specific Alexa Fluor 633 and
488 (described above), for immunofluorescence dual-labeling staining. Alexa Fluor 633
was used against anti-p-SMAD2/3 antibody. Alexa Fluor 488 was used against antiSMAD4 antibody. Paxillin, αSMA and vinculin primary antibodies (Santa Cruz
biotechnology, Inc. Santa Cruz, CA) were used in 1:250 dilutions. Species specific alexa
Fluor 488 was used against αSMA antibody.Species specific alexa Fluor 633 was used
against αSMA antibody. Rest of the experiment was performed as described in the
previous chapter.
Quantitative real-time polymerase chain reaction: Gene expression (mRNA) levels
from mice liver tissue and hepatic stellate cell samples were measured by quantitative
real-time reverse transcription-polymerase chain reaction (qRT-PCR) as described in
previous chapter. The primers used for real time PCR in 5’to 3’ orientations are rat
BAMBI

(Forward:

GCGGGGCGTCAATGGATCGC,

Reverse:

GAACTCAGAAGGCCTTCAAGG).
Western blot: Western blot from in vivo and in vitro samples were performed according
to our previous publication (18). Primary antibodies BAMBI, β actin, αSMA, CTGF
(Abcam, MA), phospho SMAD2/4, total SMAD2/3 (Cell Signaling Technology, MA),
phospho STAT3 (Santa Cruz biotechnology, Inc. Santa Cruz, CA) were used at
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recommended dilutions, and compatible horseradish peroxidase-conjugated secondary
antibodies were used.
Statistics: As described previously.
5.3 RESULTS:
SsnB treatment decreases hepatic stellate cell activation in murine NASH: Hepatic
stellate cells reside in the sinusoidal endothelium space of the liver and play a key role to
induce fibrosis in the liver. Upon activation in NASH, the quiescent hepatic stellate cells
transform into fibrogenic myofibroblasts and produce alpha smooth muscle actin protein
(αSMA). αSMA is a reliable marker to detect hepatic stellate cell activation in the liver.
We have already shown in the previous chapter that SsnB administration ameliorates
fibrotic scars in NASH liver. Our immunofluorescence data showed that SsnB
administration significantly decreased αSMA expression compared to NASH mouse liver
(Figure 5.1 A, B).
SsnB treatment in NASH mice upregulates BAMBI in liver: Studies have shown than
TLR4 signaling activation can induce increased hepatic fibrosis by downregulating TGFβ
pseudo receptor BAMBI. BAMBI is TGF-β type I receptor lacking an intracellular kinase
domain. So it blocks signal transduction even after stimulation with TGF-beta
superfamily ligands (161-163). Interestingly, immunohistochemistry of BAMBI on
mouse liver sections showed that, BAMBI immunoreactivity was significantly decreased
in NASH group compared to the Control group. However, NASH mice treated with SsnB
(NASH+SsnB group) showed considerably increased immunoreactivity of BAMBI
compared to NASH liver tissues (Figure 5.2 A, B).
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SsnB treatment decreases fibronectin deposition in NASH liver: Fibronectin is an
extracellular matrix (ECM) protein and its expression is stimulated by TGFβ signaling
pathway (164). It is also known to play an important role in liver fibrosis (20).
Interestingly, immunohistochemistry of fibronectin on mouse liver sections showed that,
fibronectin immunoreactivity was significantly increased in NASH group in the
sinusoidal area compared to the Control group. However, NASH mice treated with SsnB
(NASH+SsnB group) showed considerably decreased immunoreactivity of fibronectin
compared to NASH liver tissues (Figure 5.3A, B).
SsnB upregulates BAMBI and decreases TGFβ signaling in vitro: Upon activated by
TGFβ ligands and PAMPS, quiescent hepatic stellate cells (HSC) become profibrogenic
myofibroblasts and are primarily responsible to induce hepatic fibrogenesis in NASH by
producing excessive extracellular matrix proteins (165, 166). Interestingly, our in vitro
data from rat primary hepatic stellate cells show that LPS treatment decreases BAMBI
mRNA and protein expression compared to untreated or control cells. However,
LPS+SsnB treated cells augmented BAMBI mRNA and protein expression compared to
only LPS treated cells (Figure.5.4 A, B). SsnB treatment also decreased SMAD2/3,
SMAD4 co-localization compared to only LPS treated LX2 cells (transformed human
hepatic stellate cells) (Figure.5.4 C). Phosphorylation of SMAD2/3 protein was also
decreased upon SsnB treatment compared to the LPS treated cells (Figure.5.4 D).
SsnB downregulates STAT3 phosphorylation, decreases stellate cell activation and
connective tissue growth factor in vitro: STAT3 inhibition is known to suppress
hepatic stellate cell mediated fibrogenesis (167). STAT3 also cooperates with TGFβ1 in
activation and anti-apoptosis of hepatic stellate cells (168). TGFβ is also known to
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activate JAK1-STAT3 axis to augment liver fibrosis in coordination of SMAD mediated
signaling pathway (159). We wanted to see whether SsnB modulates STAT3 activation in
LX2 cells. Western blot experiment showed that SsnB treatment decreases STAT3
phosphorylation, αSMA and CTGF protein expression compared to LPS treated LX2
cells (Figure.5.5).
SsnB treatment decreases focal adhesion associated adaptor protein expression and
inhibits stress fiber formation in vitro: Paxillin is a multi-domain focal-adhesion
adaptor protein located at the edge between the plasma membrane and cytoskeleton. It
helps in the process of cell adhesion and acts as a scaffold to bind many signaling
proteins to the cell membrane (169). Immunofluorescent imaging of paxillin (Figure 5.6
A, B) shows that Control and LPS stimulated LX2 cells displayed heterogeneous
adhesions which are large and elongated at the periphery of the cells. However, SsnB
treatment on LX2 cells significantly decreases paxillin immunoreactivity at the periphery.
The focal adhesion regions in SsnB treated cells are smaller than Control or LPS treated
cells. While lower concentration of SsnB (10µM) decreased paxillin expression at the
periphery of LX2 cells, higher concentration of SsnB further abrogated this focal
adhesion adaptor protein expression and altered the cell morphology (Figure 5.6A,B).
Maturation of focal adhesions fuels the assemblage of adhesion-associated actin bundles
known as radial stress fibers (170). We have already seen in Figure5.5 that LPS treatment
in LX2 cells increased αSMA protein expression compared to untreated or control cells.
SsnB treatment decreased αSMA protein expression in LPS stimulated LX2 cells. In
Figure 5.6C, immunofluorescent staining of αSMA specifically depicts the stress fiber
morphology on LX2 cells. We observed that, SsnB treatment bocks the stress fiber
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formation compared to LPS treated cells as indicated by immunoreactivity of αSMA
(red) and vinculin (green). The cell morphology also changed upon SsnB treatment. They
have smaller cell body, extended cell processes and they also lose stress fibers-similar to
the quiescent stellate cells (171).
.5.4 DISCUSSION:
Intestinal microflora and a functional TLR4 (but not TLR2) are essential for hepatic
fibrogenesis. TLR4 activation can induce hepatic stellate cell proliferation and
extracellular matrix deposition in the liver, resulting in liver scarring in chronic liver
diseases. Increased TLR4 signaling in hepatic stellate cells induces chemokine secretion
and chemotaxis of macrophages but downregulates TGFβ pseudoreceptor bone
morphogenetic protein and activin membrane bound inhibitor (BAMBI) and thus
sensitizes the HSCs to TGFβ induced activation and myofibroblastic differentiation
(161). We observed that SsnB treatment decreased hepatic stellate cell activation in vivo
as indicated by αSMA immunoreactivity. TLR4 activation induces NF-κBp50:HDAC1
interaction which represses transcription of BAMBI promoter (163). BAMBI is TGFβ
type I receptor lacking an intracellular kinase domain. It blocks signal transduction even
after stimulation with TGFβ superfamily ligands. Thus, decrease of BAMBI on hepatic
stellate cells can increase TGFβ signaling and fibrogenesis (161, 163). As abrogation of
TLR4 signaling induces BAMBI mediated inhibition of pro-fibrogenic TGFβ signaling
pathway, a TLR4 antagonist like SsnB have the potency to decrease TLR4 mediated
hepatic fibrosis. Here we found that SsnB treated NASH mice had upregulated BAMBI
expression in liver which corresponds to decreased fibrogenesis.

Fibronectin, a

multifunctional glycoprotein and extracellular matrix (ECM) component is produced by
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hepatic stellate cells and is required to support other extracellular matrix protein assembly
(65, 172). We have previously shown that, BDCM induced TGFβ signaling induces
fibronectin protein expression in the NASH liver (20). Here we have observed that SsnB
induced decreased stellate cell activation and TGFβ signaling through BAMBI
upregulation which resulted in decreased fibronectin expression. From the histological
data of picrosirius red stained liver slices in the previous chapter, we saw that SsnB
treatment significantly decreased fibrotic scar deposition compared to NASH liver.
Decreased fibronectin deposition upon SsnB treatment might be responsible in decreased
collagen matrix accumulation in the liver. As hepatic stellate cells are the major
fibrogenic cells in the liver, we wanted to see if SsnB mediated repression of TGFβ
signaling by BAMBI upregulation is stellate cell dependent. Interestingly, we found that
SsnB upregulates BAMBI in vitro. TGFβ signals by binding to TGFβRI an TGFβRII
transmembrane proteins, each having serine/threonine kinase Ligand binding to this
receptor protein complex, phosphorylates and activates TGFβRI by the cytoplasmic
kinase domains of TGFβRII Activated TGFβRI phosphorylates SMAD2 and SMAD3
which can form a complex with SMAD4 and assemble in the nucleus to initiate target
gene expression in a SMAD dependent pathway (173). We found that SsnB decreased
LPS induced TGFβ signaling by decreasing SMAD2/3 phosphorylation. SsnB induced
reduction of TGFβ signaling was further confirmed by decreased co-localization of
SMAD4 and phosphorylated SMAD2/3 in the nucleus in vitro. TGFβRI can also signal
through non-SMAD pathways (174). It has been recently discovered that activated TGFβ
signaling can also phosphorylate STAT3 and thus activates JAK1-STAT3 axis in
coordination with SMAD pathway to induce TGFβ mediated fibrotic response in hepatic
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stellate cells (159). Our in vitro data shows that SsnB decreased STAT3 phosphorylation
in hepatic stellate cells and also downregulates αSMA and CTGF (connective tissue
growth factor) protein levels. Both of these proteins are key players in fibrotic
proliferation of myofibroblasts and are downstream mediators of TGFβ signaling (175).
SsnB mediated downregulation of both αSMA and CTGF in hepatic stellate cells can be
instrumental to decrease pro-fibrogenic cell proliferation. It is known that phosphorylated
STAT3 localization to the focal adhesions increases the aggressive clinical behavior of
proliferative cells. STAT3 is known to be required for cell motility (176). Focal adhesion
plays an important role in liver fibrosis through activating hepatic stellate cells and
induces TGFβ driven pro-fibrotic responses (144). αSMA is vital for focal adhesion
maturation in myofibroblasts Activated myofibroblasts incorporate αSMA in stress
fibers. αSMA has been found to decrease the intracellular mechanical stress on focal
adhesions and induces their supermaturation (177).We found that, SsnB treatment
changes the cell morphology of hepatic stellate cells. SsnB (100μM) treated LX2 cells
became smaller, possessed less stress fibers and acquired a dendritic morphology. SsnB
also induced αSMA filament disassembly and abolished focal adhesions. Inhibition focal
adhesions and stress fibers of hepatic stellate cells by higher concentrations of SsnB can
be crucial to inhibit stellate cell migration and it can also stop the stellate cells from
acquiring a fibrogenic phenotype.
To our knowledge, this is the first study reported to show the effects of SsnB on
suppression of hepatic fibrogenesis through downregulation of a myriad of cell signaling
pathways. In future, due to the strong anti-angiogenic and anti-proliferative properties of
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SsnB, it will be interesting test the therapeutic effect of SsnB to improve the
pathophysiological conditions in liver cancer and other fibrotic diseases.
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Figure 5.1 SsnB treatment decreases hepatic stellate cell activation in murine NASH. A:
Representative images of αSMA immunoreactivity as shown by immunofluorescence
microscopy on liver slices of Control, NASH and NASH+SsnB mice, taken at ×20
magnification using immunofluorescence microscopy. B: Morphometric analysis of
αSMA immunoreactivity in A. (*P < 0.05).
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Figure 5.2 SsnB treatment in NASH mice upregulates BAMBI in liver. A: Representative
images of BAMBI immunoreactivity as shown by immunohistochemistry on liver slices
of Control, NASH and NASH+SsnB mice, taken at ×20 magnification. B: Morphometric
analysis of BAMBI immunoreactivity in A. (*P < 0.05).
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Figure 5.3 SsnB treatment decreases fibronectin deposition in NASH liver. A:
Representative images of fibronectin immunoreactivity as shown by
immunohistochemistry on liver slices of Control, NASH and NASH+SsnB mice, taken at
×20 magnification. B: Morphometric analysis of fibronectin immunoreactivity in A. (*P
< 0.05).
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Figure 5.4 SsnB upregulates BAMBI and decreases TGFβ signaling in vitro. A: qRTPCR analysis of mRNA expression of BAMBI from control (untreated), LPS-treated, and
LPS+SsnB treated rat primary hepatic stellate cells, normalized against control (*P <
0.05). B. Western blot analysis of β-actin and BAMBI protein levels of Control
(untreated), LPS-treated, and LPS+SsnB treated rat primary hepatic stellate cells. C.
Immunofluorescence dual labeling depicting SMAD2/3 (red)-SMAD4 (green) colocalization (yellow) on Control (untreated), LPS-treated, and LPS+SsnB treated human
immortalized hepatic stellate cells (LX2) taken at ×40 magnification. D. Western blot
analysis of phospho SMAD2/3, total SMAD2/3 and β actin protein levels of Control
(untreated), LPS-treated, and LPS+SsnB (10/100µM) treated human immortalized
hepatic stellate cells (LX2).
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Figure 5.5 SsnB downregulates STAT3 phosphorylation, decreases stellate cell activation
and connective tissue growth factor in vitro. A: Western blot analysis of phospho STAT3,
αSMA, CTGF and β actin protein levels of Control (untreated), LPS-treated, and
LPS+SsnB (10/100µM) treated human immortalized hepatic stellate cells (LX2).
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Figure 5.6 SsnB treatment decreases focal adhesion protein expression and inhibits stress
fiber formation in vitro. A: Immunofluorescence microscopy depicting paxillin (green)
immunoreactivity in Control (untreated), LPS-treated, and LPS+SsnB(10/100µM) treated
human immortalized hepatic stellate cells (LX2) taken at ×20 magnification B:
Immunofluorescence microscopy depicting paxillin (green) immunoreactivity at ×40
magnification in Control (untreated), LPS-treated, and LPS+SsnB(100µM) treated human
immortalized hepatic stellate cells (LX2). Paxillin immunoreactivity (on the edges of the
cells) is pointed by white arrows. C: Immunofluorescence dual labeling depicting
αSMA(red)-Vinculin(green)
on
Control
(untreated),
LPS-treated,
and
LPS+SsnB(100µM) treated human immortalized hepatic stellate cells (LX2) taken at ×40
magnification. αSMA immunoreactivity (as stress fibers) is pointed by white arrows.
Nucleus
is
stained
with
DAPI
(blue).
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CHAPTER 6
CONCLUSION
Nonalcoholic steatohepatitis (NASH) is a hepatic manifestation of metabolic syndrome
which arises due to fat accumulation in liver. According to the most recognized model of
“two-hits” or "multiple-hits” hypothesis of NASH, the primary hit comes from steatosis
or lipid accumulation in the liver. The primary hit makes the liver more vulnerable to the
secondary hits- like oxidative stress, subsequent lipid peroxidation, proinflamatory
cytokines, adipokines and mitochondrial dysfunction. Together they are able to induce
hepatic injury, severe inflammation and fibrosis in the liver (105, 178). Our lab has
previously established that chronic low exposure to Bromodichloromethane (BDCM), a
drinking water disinfection byproduct, causes nonalcoholic steatohepatitis (NASH) in a
diet induced obese mice model where CYP2E1 mediated oxidative stress plays an
important pathogenic role as a “second hit” (17) of NASH progression. I have studied
molecular mechanisms by which BDCM induces hepatic inflammation and fibrosis. I
have also looked at the anti-inflammatory and anti-fibrotic effects of a plant derived
compound called Sparstolonin B, in vivo and in vitro models of hepatic injury.
It is known that upregulation of NADPH oxidase (NOX), plays a major role in the
activation process of hepatic myofibroblasts (179). However, the molecular mechanisms
that link NADPH oxidase activation and upregulation of transforming growth factor
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(TGFβ) signaling have been indistinct. Here, I have investigated the role of leptinmediated upregulation of NADPH oxidase and increased expression of microRNA 21
(miR21) in hepatic fibrogenesis. Human NASH liver samples and a high-fat (60% kcal)
diet-fed BDCM induced mouse NASH model were used for this study. Mice lacking in
genes for p47phox, leptin and miR21 were used to prove the role of the leptin-NADPH
oxidase-miR21 axis. Our results showed that oxidative stress was significantly increased
in wild-type (C57BL/6 background) mice NASH model and human NASH liver samples.
These samples also showed increased p47phox expression, induced NF-κB activation and
increased miR21. Both wild type mice NASH model and human NASH liver samples
showed increased TGFβ signaling, increased SMAD2/3 and SMAD4 co-localizations in
the nucleus, increased immunoreactivity against extracellular matrix markers with an
associated decrease in protein concentration of SMAD7, an antagonist of TGFβ signaling
pathway. NADPH oxidase activation has been shown in fibrogenesis, however, there are
no known studies linking NADPH oxidase-based oxidative stress signaling through profibrogenic miRNA expression and TGFβ signaling. This was the first study that
elucidates the role of leptin mediated NADPH oxidase in the induction of miR21 in a
murine NASH model as well as in human NASH liver samples (20). This research
revealed some interesting mechanisms by which leptin-mir21 axis can induce hepatic
injury by increasing inflammation, oxidative stress and fibrogenesis in NASH liver. Thus,
mir21 can be considered as an important therapeutic target to mitigate NASH
pathogenesis.
Apart from exploring the basic mechanisms of hepatic injury in NASH, I have
also investigated the hepatoprotective effects of Sparstolonin B (SsnB), an isocoumarin
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isolated from Sparganium stoloniferum. This herb has historically been used in traditional
Chinese herbal medicine as an anti-inflammatory, anti-cancer drug. SsnB has been
shown to disrupt TLR4 and TLR2 dependent downstream signaling pathways, including
NfkB and MAPK (102). We are the first group to test the therapeutic effect of this
compound in NASH. Interestingly, I observed that SsnB administration attenuated
hepatic inflammation and serum alanine aminotransferase (ALT) in a BDCM induced
mice model of early NASH. SsnB also showed decreased gene and protein expression of
proinflammatory cytokines in vivo and in vitro. Kupffer cell activation was also
significantly decreased by SsnB as evidenced by reduction in CD68 and monocyte
chemoattractant protein 1 (MCP1) mRNA and protein levels with associated inhibition of
macrophage infiltration in liver. Mechanistically, SsnB abrogated TLR4 trafficking to the
lipid rafts, as evidenced by the co-localization of TLR4 and lipid raft marker flotillin in
liver tissues and immortalized kupffer cells. As we have shown previously that NADPH
oxidase drives TLR4 trafficking in NASH, we studied the role of SsnB in modulating this
pathway. SsnB also seems to inhibit peroxynitrite mediated oxidative stress by
deactivating NADPH oxidase (19).
SsnB has also been characterized as anti-proliferative drug which induced cell
cycle arrest in neuroblastoma cells. It could also induce apoptosis and promote cell death
in cancer cells (103). I have established anti-fibrotic and anti-proliferative mechanisms of
SsnB in a BDCM induced murine model of NASH and in hepatic stellate cell (HSC)
culture. I have found that SsnB shows a promising role to decrease liver fibrosis by
reducing TLR4-PI3K mediated pro-inflammatory signaling pathway. It is known that
activated TLR4-PI3K pathway can induce p53 degradation by upregulating MDM2
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(133). Recent research shows that senescence induction in fibrogenic cells by the increase
of p21, p53 can help to reduce excessive fibroblast proliferation and suppress hepatic
tumor (134). However, no research has focused on the possible mechanism of senescence
induction by antagonizing TLR4-PI3k -MDM2 signaling. My work shows that SsnB
antagonizes TLR4-PI3k signaling by upregulating PTEN protein expression. It further
lowers MDM2 activation and thus increases p53 and p21 gene and protein expression.
SsnB also decreased TGFβ signaling by upregulating TGFβ pseudo-receptor BAMBI in
vivo. As HSCs are the major fibrogenic cells in the liver, I wanted to see the therapeutic
effect of SsnB on these cells. SsnB treatment also downregulated gene expression of profibrogenic hedgehog signaling pathway markers (Ihh, Shh, Gli1, Gli2) in HSCs. SsnB
also arrested cell cycle at G2-M phase and induced apoptosis in HSCs. In vitro
experiments on rat and human HSCs showed that SsnB treatment increased gene and
protein expression of BAMBI and decreased nuclear co-localization of phospho
SMAD2/3 and SMAD4 protein. A decrease in phosphorylated SMAD2/3 protein upon
SsnB administration in HSCs further confirms the inhibitory effects of SsnB on TGFβ
signaling. SsnB decreased STAT3 phosphorylation, downregulated hepatic stellate cell
activation and extracellular matrix protein synthesis. We also found that SsnB diminishes
the fibroblastic morphology of hepatic stellate cells by downregulating focal adhesion
associated adaptor protein and attenuating the stress fiber formation. this research
unravels a novel mechanistic approach to diminish fibrogenesis in NASH through
inhibiting a myriad of pro-fibrogenic signaling pathways by SsnB.
Although our research has shown promising anti-inflammatory and anti-fibrotic
potential of SsnB, our results are constrained within limited scope of experiments. It will
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be interesting to establish a therapeutic model of NASH where mice with full blown
NASH will be administered with SsnB after the disease development. To increase
absorption and bioavailability of SsnB, it will be interesting if SsnB can be coupled with
nanoparticle to facilitate targeted delivery and controlled release. SsnB mediated
alteration of metabolic pathways and steatosis regulation will be worth exploring. As
SsnB has shown itself to be a strong anti-angiogenic and anti-proliferative molecule, it
will be interesting to see the therapeutic effect of SsnB on liver cancer and other fibrotic
diseases.
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